The	The	DT	0
Antihypertensive	Antihypertensive	NNP	B-NP
and	and	CC	0
lowering	lowering	VBG	B-NP
treatment	treatment	NN	I-NP
lipid	lipid	NN	I-NP
to	to	TO	0
Prevent	Prevent	VB	0
Heart	Heart	NNP	B-NP
Attack	Attack	NNP	I-NP
Trial	Trial	NNP	I-NP
(	(	-LRB-	0
ALLHAT	ALLHAT	NNP	0
)	)	-RRB-	0
is	is	VBZ	0
a	a	DT	0
randomized	randomized	NN	0
,	,	,	0
clinical	clinical	JJ	B-NP
trial	trial	NN	I-NP
two-component	two-component	JJ	I-NP
sponsored	sponsored	VBN	0
by	by	IN	0
the	the	DT	0
National	National	NNP	B-NP
Heart	Heart	NNP	I-NP
,	,	,	0
Lung	Lung	NNP	0
,	,	,	0
and	and	CC	0
Blood	Blood	NNP	0
Institute	Institute	NNP	0
(	(	-LRB-	0
NHLBI	NHLBI	NNP	B-NP
)	)	-RRB-	0
.	.	.	0
A	A	DT	0
double-blind	double-blind	JJ	B-NP
,	,	,	0
active-controlled	active-controlled	JJ	0
hypertension	hypertension	NN	0
component	component	NN	0
is	is	VBZ	0
designed	designed	VBN	0
to	to	TO	0
compare	compare	VB	0
the	the	DT	0
rate	rate	NN	0
of	of	IN	0
fatal	fatal	JJ	B-NP
coronary	coronary	JJ	I-NP
heart	heart	NN	I-NP
disease	disease	NN	I-NP
(	(	-LRB-	0
coronary	coronary	JJ	B-NP
heart	heart	NN	I-NP
disease	disease	NN	I-NP
)	)	-RRB-	0
or	or	CC	0
nonfatal	nonfatal	NN	B-NP
myocardial	myocardial	NN	I-NP
infarction	infarction	NN	I-NP
(	(	-LRB-	0
MI	MI	NNP	0
)	)	-RRB-	0
(	(	-LRB-	0
the	the	DT	0
primary	primary	JJ	B-NP
endpoint	endpoint	NN	I-NP
)	)	-RRB-	0
in	in	IN	0
hypertensive	hypertensive	JJ	B-NP
participant	participant	NN	I-NP
high-risk	high-risk	JJ	I-NP
,	,	,	0
aged	aged	VBN	0
55	55	CD	0
years	years	NNS	0
or	or	CC	0
older	older	JJR	0
,	,	,	0
between	between	IN	0
those	those	DT	0
randomized	randomized	NN	0
to	to	TO	0
treatment	treatment	VB	0
initiated	initiated	VBN	0
with	with	IN	0
a	a	DT	0
diuretic	diuretic	NN	B-NP
(	(	-LRB-	0
chlorthalidone	chlorthalidone	LS	B-NP
)	)	-RRB-	0
and	and	CC	0
treatment	treatment	NN	0
initiated	initiated	VBN	0
with	with	IN	0
each	each	DT	0
of	of	IN	0
three	three	CD	0
alternative	alternative	NN	B-NP
antihypertensive	antihypertensive	NN	I-NP
drug	drug	NN	I-NP
:	:	:	0
a	a	DT	0
calcium-channel	calcium-channel	JJ	B-NP
blocker	blocker	NN	I-NP
(	(	-LRB-	0
amlodipine	amlodipine	LS	B-NP
)	)	-RRB-	0
,	,	,	0
an	an	DT	0
angiotensin-converting	angiotensin-converting	JJ	B-NP
enzyme	enzyme	NN	I-NP
(	(	-LRB-	I-NP
ACE	ACE	NNP	I-NP
)	)	-RRB-	I-NP
-inhibitor	-inhibitor	NNP	I-NP
(	(	-LRB-	0
lisinopril	lisinopril	LS	B-NP
)	)	-RRB-	0
,	,	,	0
or	or	CC	0
an	an	DT	0
alpha-adrenergic	alpha-adrenergic	JJ	B-NP
blocker	blocker	NN	I-NP
(	(	-LRB-	0
doxazosin	doxazosin	LS	B-NP
)	)	-RRB-	0
.	.	.	0
An	An	DT	0
open-label	open-label	JJ	B-NP
lipid-lowering	lipid-lowering	JJ	I-NP
component	component	NN	I-NP
is	is	VBZ	0
designed	designed	VBN	0
to	to	TO	0
determine	determine	VB	0
if	if	IN	0
lowering	lowering	VBG	B-NP
LDL	LDL	NNP	I-NP
cholesterol	cholesterol	NN	I-NP
with	with	IN	0
pravastatin	pravastatin	VBG	0
compared	compared	VBN	0
to	to	TO	0
"usual	"usual	CD	0
care	care	NN	0
"	"	''	0
reduces	reduces	VBZ	0
all-cause	all-cause	JJ	B-NP
mortality	mortality	NN	I-NP
in	in	IN	0
a	a	DT	0
subset	subset	NN	B-NP
of	of	IN	0
moderately	moderately	RB	0
hypercholesterolemic	hypercholesterolemic	JJ	B-NP
patient	patient	JJ	I-NP
.	.	.	0
Randomization	Randomization	JJ	0
to	to	TO	0
the	the	DT	0
hypertension	hypertension	JJ	0
component	component	NN	0
began	began	VBD	0
in	in	IN	0
February	February	NNP	0
,	,	,	0
1994	1994	CD	0
,	,	,	0
and	and	CC	0
continued	continued	VBD	0
through	through	IN	0
January	January	NNP	0
,	,	,	0
1998	1998	CD	0
,	,	,	0
with	with	IN	0
42,418	42,418	CD	0
participant	participant	NN	B-NP
recruited	recruited	VBN	0
at	at	IN	0
623	623	CD	0
clinical	clinical	JJ	B-NP
center	center	NN	I-NP
in	in	IN	0
the	the	DT	0
united	united	JJ	B-NP
state	state	NN	I-NP
,	,	,	0
Canada	Canada	NNP	0
,	,	,	0
Puerto	Puerto	NNP	0
Rico	Rico	NNP	0
and	and	CC	0
the	the	DT	0
US	US	NNP	0
Virgin	Virgin	NNP	0
Islands	Islands	NNPS	0
.	.	.	0
Randomization	Randomization	NNP	B-NP
of	of	IN	0
10,355	10,355	CD	0
participant	participant	NN	B-NP
into	into	IN	0
the	the	DT	0
lipid	lipid	JJ	B-NP
trial	trial	NN	I-NP
ended	ended	VBD	0
May	May	NNP	0
31	31	CD	0
,	,	,	0
1998	1998	CD	0
.	.	.	0
Follow-up	Follow-up	JJ	0
on	on	IN	0
all	all	DT	0
participant	participant	NN	B-NP
continued	continued	VBD	0
through	through	IN	0
March	March	NNP	0
,	,	,	0
2002	2002	CD	0
[	[	-LRB-	0
1	1	LS	0
]	]	-RRB-	0
.	.	.	0
Following	Following	VBG	0
independent	independent	JJ	0
reviews	reviews	NNS	0
by	by	IN	0
the	the	DT	0
Data	Data	NNP	0
and	and	CC	0
Safety	Safety	NNP	0
Monitoring	Monitoring	NNP	B-NP
Board	Board	NNP	I-NP
(	(	-LRB-	0
DSMB	DSMB	NNP	0
)	)	-RRB-	0
on	on	IN	0
January	January	NNP	0
6	6	CD	0
,	,	,	0
2000	2000	CD	0
,	,	,	0
and	and	CC	0
by	by	IN	0
an	an	DT	0
Ad	Ad	NNP	B-NP
Hoc	Hoc	NNP	I-NP
Committee	Committee	NNP	I-NP
on	on	IN	0
January	January	NNP	0
21	21	CD	0
,	,	,	0
2000	2000	CD	0
,	,	,	0
the	the	DT	0
Director	Director	NNP	0
of	of	IN	0
the	the	DT	0
National	National	NNP	B-NP
Heart	Heart	NNP	I-NP
,	,	,	0
Lung	Lung	NNP	0
,	,	,	0
and	and	CC	0
Blood	Blood	NNP	0
Institute	Institute	NNP	0
accepted	accepted	VBD	0
a	a	DT	0
recommendation	recommendation	NN	B-NP
to	to	TO	0
discontinue	discontinue	VB	0
the	the	DT	0
antihypertensive	antihypertensive	JJ	B-NP
trial	trial	NN	I-NP
doxazosin	doxazosin	JJ	I-NP
treatment	treatment	NN	I-NP
arm	arm	NN	I-NP
.	.	.	0
This	This	DT	0
recommendation	recommendation	NN	B-NP
was	was	VBD	0
based	based	VBN	0
on	on	IN	0
the	the	DT	0
low	low	JJ	0
doxazosin	doxazosin	JJ	B-NP
showing	showing	NN	I-NP
benefit	benefit	NN	I-NP
probability	probability	NN	I-NP
over	over	IN	0
primary	primary	JJ	B-NP
endpoint	endpoint	NN	I-NP
chlorthalidone	chlorthalidone	NN	I-NP
,	,	,	0
as	as	RB	0
well	well	RB	0
as	as	IN	0
the	the	DT	0
significantly	significantly	RB	0
secondary	secondary	JJ	B-NP
endpoint	endpoint	NN	I-NP
increased	increased	VBD	I-NP
occurrence	occurrence	VBN	I-NP
,	,	,	0
combined	combined	VBN	0
cardiovascular	cardiovascular	JJ	B-NP
disease	disease	NN	I-NP
(	(	-LRB-	0
cardiovascular	cardiovascular	JJ	B-NP
disease	disease	NN	I-NP
)	)	-RRB-	0
(	(	-LRB-	0
encompassing	encompassing	VBG	B-NP
chd	chd	NN	I-NP
death	death	NN	I-NP
,	,	,	0
nonfatal	nonfatal	VBG	0
MI	MI	NNP	0
,	,	,	0
stroke	stroke	NN	0
,	,	,	0
coronary	coronary	JJ	B-NP
revascularization	revascularization	JJ	I-NP
procedure	procedure	NN	I-NP
[	[	-LRB-	0
coronary	coronary	JJ	B-NP
artery	artery	NN	I-NP
bypass	bypass	NN	I-NP
graft	graft	NN	I-NP
or	or	CC	0
CABG	CABG	NNP	B-NP
,	,	,	0
percutaneou	percutaneou	NN	B-NP
transluminal	transluminal	NN	I-NP
coronary	coronary	JJ	I-NP
angioplasty	angioplasty	NN	I-NP
or	or	FW	0
PTCA	PTCA	NN	B-NP
/	/	NN	I-NP
stent	stent	NNP	I-NP
]	]	-RRB-	0
,	,	,	0
angina	angina	NNS	0
[	[	-LRB-	0
hospitalized	hospitalized	VBN	0
or	or	CC	0
treated	treated	VBN	0
as	as	IN	0
an	an	DT	0
outpatient	outpatient	NN	0
]	]	-RRB-	0
,	,	,	0
heart	heart	NN	B-NP
failure	failure	NN	I-NP
[	[	-LRB-	0
HF	HF	NNP	0
/	/	NNP	0
treated	treated	VBD	0
in	in	IN	0
the	the	DT	0
hospital	hospital	NN	0
or	or	CC	0
as	as	IN	0
an	an	DT	0
outpatient	outpatient	NN	0
]	]	-RRB-	0
,	,	,	0
and	and	CC	0
peripheral	peripheral	JJ	B-NP
arterial	arterial	JJ	I-NP
disease	disease	NN	I-NP
[	[	-LRB-	0
in-hospital	in-hospital	NNP	B-NP
or	or	CC	0
outpatient	outpatient	JJ	B-NP
revascularization	revascularization	NN	I-NP
]	]	-RRB-	0
)	)	-RRB-	0
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
arm	arm	NN	I-NP
(	(	-LRB-	0
RR	RR	NNP	B-NP
1.25	1.25	CD	0
;	;	:	0
95	95	CD	0
%	%	NN	0
CI	CI	NNP	0
,	,	,	0
1.17-1.33	1.17-1.33	NNP	0
;	;	:	0
P	P	NNP	0
<	<	SYM	0
.001	.001	NNP	0
)	)	-RRB-	0
,	,	,	0
with	with	IN	0
a	a	DT	0
doubling	doubling	NN	0
of	of	IN	0
risk	risk	NN	0
of	of	IN	0
HF	HF	NNP	B-NP
(	(	-LRB-	0
fatal	fatal	JJ	0
,	,	,	0
hospitalized	hospitalized	VBN	0
and	and	CC	0
treated	treated	VBN	0
but	but	CC	0
nonhospitalized	nonhospitalized	CD	0
)	)	-RRB-	0
(	(	-LRB-	0
RR	RR	NNP	B-NP
2.04	2.04	CD	0
;	;	:	0
95	95	CD	0
%	%	NN	0
CI	CI	NNP	0
,	,	,	0
1.79-2.32	1.79-2.32	NNP	0
;	;	:	0
P	P	NNP	0
<	<	SYM	0
.001	.001	NNP	0
)	)	-RRB-	0
.	.	.	0
When	When	WRB	0
only	only	RB	0
fatal	fatal	JJ	0
and	and	CC	0
hospitalized	hospitalized	VBN	B-NP
HF	HF	NNP	I-NP
were	were	VBD	0
analyzed	analyzed	VBN	0
,	,	,	0
the	the	DT	0
large	large	JJ	0
difference	difference	NN	0
remained	remained	VBD	0
(	(	-LRB-	0
RR	RR	NNP	B-NP
1.83	1.83	CD	0
;	;	:	0
95	95	CD	0
%	%	NN	0
CI	CI	NNP	0
,	,	,	0
1.58-2.13	1.58-2.13	NNP	0
;	;	:	0
P	P	NNP	0
<	<	SYM	0
.001	.001	NNP	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
findings	findings	NNS	0
and	and	CC	0
operational	operational	JJ	B-NP
aspect	aspect	NN	I-NP
of	of	IN	0
stopping	stopping	VBG	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
arm	arm	NN	I-NP
of	of	IN	0
the	the	DT	0
study	study	NN	0
have	have	VBP	0
been	been	VBN	0
previously	previously	RB	0
described	described	VBN	0
[	[	-LRB-	0
2	2	CD	0
3	3	CD	0
4	4	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
observed	observed	JJ	0
increase	increase	NN	0
in	in	IN	0
HF	HF	NNP	B-NP
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
as	as	IN	0
compared	compared	VBN	0
to	to	TO	0
the	the	DT	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
led	led	VBD	0
to	to	TO	0
several	several	JJ	0
additional	additional	JJ	0
analyses	analyses	NNS	0
aimed	aimed	VBN	0
toward	toward	IN	0
validation	validation	NN	B-NP
of	of	IN	0
the	the	DT	0
diagnoses	diagnoses	NN	0
,	,	,	0
with	with	IN	0
a	a	DT	0
focus	focus	NN	0
on	on	IN	0
hospitalized	hospitalized	NN	0
and	and	CC	0
fatal	fatal	JJ	B-NP
HF	HF	NNP	I-NP
.	.	.	0
The	The	DT	0
purposes	purposes	NNS	0
of	of	IN	0
these	these	DT	0
analyses	analyses	NNS	0
were	were	VBD	0
:	:	:	0
1	1	LS	0
)	)	-RRB-	0
to	to	TO	0
evaluate	evaluate	VB	0
the	the	DT	0
reality	reality	NN	0
of	of	IN	0
hf	hf	NN	B-NP
case	case	NN	I-NP
,	,	,	0
i.e.	i.e.	FW	0
whether	whether	IN	0
diagnosis	diagnosis	NN	0
,	,	,	0
management	management	NN	0
,	,	,	0
and	and	CC	0
clinical	clinical	JJ	B-NP
course	course	NN	I-NP
were	were	VBD	0
what	what	WP	0
might	might	MD	0
be	be	VB	0
expected	expected	VBN	0
,	,	,	0
and	and	CC	0
2	2	LS	0
)	)	-RRB-	0
to	to	TO	0
compare	compare	VB	0
these	these	DT	0
features	features	NNS	0
between	between	IN	0
the	the	DT	0
two	two	CD	0
treatment	treatment	NN	B-NP
group	group	NN	I-NP
.	.	.	0
Methods	Methods	NNP	0
Study	Study	NNP	0
Design	Design	NNP	0
The	The	DT	0
rationale	rationale	NN	0
and	and	CC	0
design	design	NN	0
of	of	IN	0
ALLHAT	ALLHAT	NNP	B-NP
are	are	VBP	0
described	described	VBN	0
in	in	IN	0
detail	detail	NN	0
elsewhere	elsewhere	RB	0
[	[	-LRB-	0
1	1	LS	0
]	]	-RRB-	0
.	.	.	0
Briefly	Briefly	RB	0
,	,	,	0
those	those	DT	0
eligible	eligible	NN	0
for	for	IN	0
randomization	randomization	NN	B-NP
had	had	VBD	0
systolic	systolic	JJ	B-NP
blood	blood	NN	I-NP
pressure	pressure	NN	I-NP
(	(	-LRB-	0
systolic	systolic	NN	B-NP
blood	blood	NN	I-NP
pressure	pressure	NN	I-NP
)	)	-RRB-	0
of	of	IN	0
at	at	IN	0
least	least	JJS	0
140	140	CD	0
mm	mm	JJ	B-NP
Hg	Hg	NNP	I-NP
and	and	CC	0
/	/	NNP	0
or	or	CC	0
diastolic	diastolic	JJ	B-NP
blood	blood	NN	I-NP
pressure	pressure	NN	I-NP
of	of	IN	0
at	at	IN	0
least	least	JJS	0
90	90	CD	0
mm	mm	JJ	B-NP
Hg	Hg	NNP	I-NP
,	,	,	0
or	or	CC	0
took	took	VBD	0
medication	medication	NN	0
for	for	IN	0
hypertension	hypertension	NN	0
,	,	,	0
and	and	CC	0
had	had	VBD	0
at	at	IN	0
least	least	JJS	0
one	one	CD	0
other	other	JJ	0
chd	chd	NN	B-NP
event	event	NN	I-NP
risk	risk	NN	I-NP
factor	factor	NN	I-NP
.	.	.	0
risk	risk	NN	B-NP
factor	factor	NN	I-NP
included	included	VBD	0
previous	previous	JJ	0
MI	MI	NNP	0
or	or	CC	0
stroke	stroke	NN	0
,	,	,	0
left	left	VBD	0
ventricular	ventricular	JJ	B-NP
hypertrophy	hypertrophy	NN	I-NP
by	by	IN	0
electrocardiogram	electrocardiogram	NN	0
or	or	CC	0
echocardiogram	echocardiogram	NN	B-NP
,	,	,	0
history	history	NN	0
of	of	IN	0
type	type	NN	0
2	2	CD	0
diabetes	diabetes	NN	0
,	,	,	0
current	current	JJ	0
cigarette	cigarette	NN	0
smoking	smoking	NN	0
,	,	,	0
and	and	CC	0
low	low	JJ	0
high-density	high-density	JJ	B-NP
lipoprotein	lipoprotein	NN	I-NP
(	(	-LRB-	0
high-density	high-density	NN	B-NP
lipoprotein	lipoprotein	NN	I-NP
)	)	-RRB-	0
level	level	NN	0
.	.	.	0
The	The	DT	0
primary	primary	JJ	B-NP
endpoint	endpoint	NN	I-NP
of	of	IN	0
the	the	DT	0
blood	blood	NN	B-NP
pressure	pressure	NN	I-NP
(	(	-LRB-	0
blood	blood	NN	B-NP
pressure	pressure	NN	I-NP
)	)	-RRB-	0
trial	trial	NN	0
is	is	VBZ	0
the	the	DT	0
composite	composite	JJ	0
of	of	IN	0
nonfatal	nonfatal	JJ	B-NP
MI	MI	NNP	I-NP
and	and	CC	0
fatal	fatal	JJ	B-NP
CHD	CHD	NNP	I-NP
.	.	.	0
The	The	DT	0
four	four	CD	0
protocol-defined	protocol-defined	JJ	B-NP
secondary	secondary	JJ	I-NP
clinical	clinical	JJ	I-NP
outcome	outcome	NN	I-NP
are	are	VBP	0
all-cause	all-cause	JJ	B-NP
mortality	mortality	NN	I-NP
,	,	,	0
combined	combined	VBN	0
coronary	coronary	JJ	B-NP
heart	heart	NN	I-NP
disease	disease	NN	I-NP
(	(	-LRB-	0
including	including	VBG	B-NP
CHD	CHD	NNP	I-NP
death	death	NN	I-NP
,	,	,	0
nonfatal	nonfatal	VBG	0
MI	MI	NNP	0
,	,	,	0
coronary	coronary	JJ	B-NP
revascularization	revascularization	JJ	I-NP
procedure	procedure	NN	I-NP
and	and	CC	0
hospitalized	hospitalized	JJ	0
angina	angina	NN	0
)	)	-RRB-	0
,	,	,	0
stroke	stroke	NN	0
,	,	,	0
and	and	CC	0
combined	combined	JJ	0
cardiovascular	cardiovascular	JJ	B-NP
disease	disease	NN	I-NP
(	(	-LRB-	0
including	including	VBG	B-NP
CHD	CHD	NNP	I-NP
death	death	NN	I-NP
,	,	,	0
nonfatal	nonfatal	VBG	0
MI	MI	NNP	0
,	,	,	0
stroke	stroke	NN	0
,	,	,	0
coronary	coronary	JJ	B-NP
revascularization	revascularization	JJ	I-NP
procedure	procedure	NN	I-NP
,	,	,	0
angina	angina	VBD	0
treated	treated	VBN	0
in	in	IN	0
the	the	DT	0
hospital	hospital	NN	0
or	or	CC	0
as	as	IN	0
an	an	DT	0
outpatient	outpatient	NN	0
,	,	,	0
lower	lower	JJR	0
extremity	extremity	JJ	0
peripheral	peripheral	JJ	B-NP
arterial	arterial	JJ	I-NP
disease	disease	NN	I-NP
treated	treated	VBN	0
in	in	IN	0
the	the	DT	0
hospital	hospital	NN	0
or	or	CC	0
with	with	IN	0
outpatient	outpatient	JJ	B-NP
revascularization	revascularization	NN	I-NP
,	,	,	0
and	and	CC	0
HF	HF	NNP	B-NP
,	,	,	0
fatal	fatal	JJ	0
or	or	CC	0
treated	treated	VBN	0
in	in	IN	0
the	the	DT	0
hospital	hospital	NN	0
or	or	CC	0
as	as	IN	0
an	an	DT	0
outpatient	outpatient	NN	0
)	)	-RRB-	0
.	.	.	0
The	The	DT	0
hf	hf	NN	B-NP
diagnosis	diagnosis	VBD	I-NP
validation	validation	NN	I-NP
entailed	entailed	VBN	0
answering	answering	VBG	0
several	several	JJ	0
questions	questions	NNS	0
:	:	:	0
1	1	LS	0
.	.	.	0
Did	Did	VBD	0
hf	hf	NN	B-NP
case	case	NN	I-NP
meet	meet	VBP	0
allhat	allhat	NN	B-NP
diagnostic	diagnostic	JJ	I-NP
criterion	criterion	NN	I-NP
?	?	.	0
2	2	LS	0
.	.	.	0
Were	Were	VBD	0
baseline	baseline	JJ	B-NP
characteristic	characteristic	JJ	I-NP
and	and	CC	0
hf	hf	NN	B-NP
case	case	NN	I-NP
medical	medical	JJ	I-NP
management	management	NN	I-NP
as	as	RB	0
expected	expected	VBN	0
and	and	CC	0
similar	similar	JJ	0
across	across	IN	0
the	the	DT	0
drug	drug	NN	B-NP
group	group	NN	I-NP
?	?	.	0
3	3	LS	0
.	.	.	0
Were	Were	VBD	0
prevalence	prevalence	JJ	0
and	and	CC	0
severity	severity	NN	0
of	of	IN	0
systolic	systolic	JJ	0
dysfunction	dysfunction	NN	0
as	as	IN	0
expected	expected	VBN	0
and	and	CC	0
similar	similar	JJ	0
across	across	IN	0
drug	drug	NN	0
groups	groups	NNS	0
?	?	.	0
4	4	LS	0
.	.	.	0
Were	Were	VBD	0
case-fatality	case-fatality	JJ	0
rates	rates	NNS	0
as	as	RB	0
expected	expected	VBN	0
and	and	CC	0
similar	similar	JJ	0
across	across	IN	0
drug	drug	NN	0
groups	groups	NNS	0
?	?	.	0
Unless	Unless	IN	0
otherwise	otherwise	RB	0
specified	specified	VBN	0
,	,	,	0
all	all	DT	0
data	data	NNS	0
for	for	IN	0
these	these	DT	0
analyses	analyses	NNS	0
were	were	VBD	0
collected	collected	VBN	0
as	as	IN	0
of	of	IN	0
December	December	NNP	0
,	,	,	0
1999	1999	CD	0
.	.	.	0
Heart	Heart	NNP	B-NP
Failure	Failure	NNP	I-NP
Diagnosis	Diagnosis	NNP	I-NP
At	At	IN	0
each	each	DT	0
follow-up	follow-up	JJ	B-NP
clinic	clinic	NN	I-NP
visit	visit	NN	I-NP
the	the	DT	0
occurrence	occurrence	NN	0
of	of	IN	0
study	study	NN	0
clinical	clinical	JJ	B-NP
event	event	NN	I-NP
was	was	VBD	0
assessed	assessed	VBN	0
,	,	,	0
and	and	CC	0
,	,	,	0
if	if	IN	0
identified	identified	VBN	0
by	by	IN	0
the	the	DT	0
clinical	clinical	JJ	B-NP
investigator	investigator	NN	I-NP
,	,	,	0
reported	reported	VBD	0
on	on	IN	0
an	an	DT	0
endpoint	endpoint	JJ	B-NP
form	form	NN	I-NP
.	.	.	0
For	For	IN	0
each	each	DT	0
event	event	NN	0
involving	involving	VBG	B-NP
hospitalization	hospitalization	NN	I-NP
,	,	,	0
a	a	DT	0
hospital	hospital	NN	B-NP
discharge	discharge	NN	I-NP
summary	summary	NN	I-NP
or	or	CC	0
expiration	expiration	NN	B-NP
summary	summary	NN	I-NP
was	was	VBD	0
to	to	TO	0
be	be	VB	0
submitted	submitted	VBN	0
,	,	,	0
and	and	CC	0
for	for	IN	0
each	each	DT	0
death	death	NN	0
a	a	DT	0
death	death	NN	B-NP
certificate	certificate	NN	I-NP
was	was	VBD	0
required	required	VBN	0
.	.	.	0
endpoint	endpoint	NN	B-NP
form	form	NN	I-NP
and	and	CC	0
supporting	supporting	VBG	0
documentation	documentation	NN	B-NP
were	were	VBD	0
reviewed	reviewed	VBN	0
at	at	IN	0
the	the	DT	0
allhat	allhat	NN	B-NP
clinical	clinical	JJ	I-NP
trial	trial	NN	I-NP
Center	Center	NNP	0
(	(	-LRB-	0
CTC	CTC	NNP	B-NP
)	)	-RRB-	0
for	for	IN	0
accuracy	accuracy	NN	B-NP
and	and	CC	0
appropriatene	appropriatene	NN	B-NP
.	.	.	0
When	When	WRB	0
a	a	DT	0
discrepancy	discrepancy	NN	0
or	or	CC	0
ambiguity	ambiguity	NN	B-NP
was	was	VBD	0
found	found	VBN	0
,	,	,	0
the	the	DT	0
CTC	CTC	NNP	B-NP
sent	sent	VBD	0
a	a	DT	0
written	written	JJ	0
query	query	NN	0
to	to	TO	0
the	the	DT	0
Principal	Principal	NNP	B-NP
Investigator	Investigator	NNP	I-NP
,	,	,	0
who	who	WP	0
retained	retained	VBD	0
the	the	DT	0
final	final	JJ	B-NP
word	word	NN	I-NP
concerning	concerning	VBG	0
the	the	DT	0
diagnosis	diagnosis	NN	0
or	or	CC	0
cause	cause	NN	0
of	of	IN	0
death	death	NN	0
.	.	.	0
A	A	DT	0
random	random	JJ	0
10	10	CD	0
%	%	NN	0
sample	sample	NN	0
of	of	IN	0
strokes	strokes	NNS	0
,	,	,	0
nonfatal	nonfatal	JJ	B-NP
mi	mi	NN	I-NP
and	and	CC	0
chd	chd	NN	B-NP
death	death	NN	I-NP
was	was	VBD	0
selected	selected	VBN	0
for	for	IN	0
blinded	blinded	JJ	0
quality	quality	NN	B-NP
control	control	NN	I-NP
evaluation	evaluation	NN	I-NP
by	by	IN	0
the	the	DT	0
allhat	allhat	NN	B-NP
endpoint	endpoint	NN	I-NP
Subcommittee	Subcommittee	NNP	0
;	;	:	0
for	for	IN	0
these	these	DT	0
cases	cases	NNS	0
additional	additional	JJ	0
documentation	documentation	NN	B-NP
was	was	VBD	0
requested	requested	VBN	0
.	.	.	0
No	No	DT	0
such	such	JJ	0
subcommittee	subcommittee	NN	B-NP
quality	quality	NN	I-NP
control	control	NN	I-NP
routine	routine	JJ	I-NP
endpoint	endpoint	NN	I-NP
was	was	VBD	0
initially	initially	RB	0
planned	planned	VBN	0
for	for	IN	0
reported	reported	VBN	B-NP
HF	HF	NNP	I-NP
.	.	.	0
However	However	RB	0
,	,	,	0
the	the	DT	0
Subcommittee	Subcommittee	NNP	0
was	was	VBD	0
subsequently	subsequently	RB	0
called	called	VBN	0
upon	upon	RP	0
to	to	TO	0
evaluate	evaluate	VB	0
a	a	DT	0
random	random	JJ	0
sample	sample	NN	0
of	of	IN	0
reported	reported	VBN	0
fatal	fatal	JJ	0
and	and	CC	0
hospitalized	hospitalized	VBN	0
nonfatal	nonfatal	JJ	B-NP
hf	hf	NN	I-NP
event	event	NN	I-NP
.	.	.	0
As	As	IN	0
this	this	DT	0
occurred	occurred	VBD	0
prior	prior	RB	0
to	to	TO	0
the	the	DT	0
termination	termination	NN	0
of	of	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
arm	arm	NN	I-NP
,	,	,	0
neither	neither	CC	0
the	the	DT	0
chair	chair	NN	0
nor	nor	CC	0
the	the	DT	0
members	members	NNS	0
of	of	IN	0
the	the	DT	0
Subcommittee	Subcommittee	NNP	0
was	was	VBD	0
informed	informed	VBN	0
of	of	IN	0
the	the	DT	0
major	major	JJ	0
reason	reason	NN	0
for	for	IN	0
this	this	DT	0
review	review	NN	0
,	,	,	0
namely	namely	RB	0
,	,	,	0
the	the	DT	0
trend	trend	NN	0
toward	toward	IN	0
a	a	DT	0
higher	higher	JJR	0
HF	HF	JJ	B-NP
event	event	NN	I-NP
rate	rate	NN	I-NP
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
compared	compared	VBN	0
to	to	TO	0
the	the	DT	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
.	.	.	0
The	The	DT	0
Subcommittee	Subcommittee	NNP	0
was	was	VBD	0
told	told	VBN	0
that	that	IN	0
the	the	DT	0
review	review	NN	0
was	was	VBD	0
undertaken	undertaken	VBN	0
at	at	IN	0
the	the	DT	0
request	request	NN	0
of	of	IN	0
the	the	DT	0
DSMB	DSMB	NNP	B-NP
to	to	TO	0
address	address	VB	0
the	the	DT	0
reliability	reliability	NN	0
and	and	CC	0
validity	validity	NN	0
of	of	IN	0
reported	reported	VBN	B-NP
hf	hf	NN	I-NP
event	event	NN	I-NP
.	.	.	0
This	This	DT	0
evaluation	evaluation	NN	0
consisted	consisted	VBD	0
of	of	IN	0
fifty	fifty	JJ	0
events	events	NNS	0
,	,	,	0
evenly	evenly	RB	0
distributed	distributed	VBN	0
across	across	IN	0
the	the	DT	0
four	four	CD	0
treatment	treatment	NN	B-NP
group	group	NN	I-NP
,	,	,	0
reported	reported	VBD	0
as	as	IN	0
fatal	fatal	JJ	0
or	or	CC	0
hospitalized	hospitalized	VBN	0
nonfatal	nonfatal	JJ	B-NP
HF	HF	NNP	I-NP
and	and	CC	0
with	with	IN	0
protocol-required	protocol-required	JJ	B-NP
documentation	documentation	NN	I-NP
(	(	-LRB-	0
discharge	discharge	JJ	B-NP
summary	summary	NN	I-NP
for	for	IN	0
hospitalized	hospitalized	JJ	0
events	events	NNS	0
,	,	,	0
death	death	NN	B-NP
certificate	certificate	NN	I-NP
for	for	IN	0
deaths	deaths	NNS	0
)	)	-RRB-	0
.	.	.	0
Additional	Additional	JJ	0
material	material	NN	0
was	was	VBD	0
not	not	RB	0
requested	requested	VBN	0
,	,	,	0
since	since	IN	0
this	this	DT	0
would	would	MD	0
have	have	VB	0
posed	posed	VBN	0
an	an	DT	0
undue	undue	JJ	0
burden	burden	NN	0
on	on	IN	0
the	the	DT	0
clinical	clinical	JJ	B-NP
site	site	NN	I-NP
staff	staff	NN	I-NP
and	and	CC	0
would	would	MD	0
have	have	VB	0
risked	risked	VBN	0
raising	raising	VBG	B-NP
question	question	NN	I-NP
about	about	IN	0
emerging	emerging	VBG	B-NP
difference	difference	NN	I-NP
among	among	IN	0
treatment	treatment	NN	B-NP
group	group	NN	I-NP
.	.	.	0
The	The	DT	0
hf	hf	NN	B-NP
allhat	allhat	NN	I-NP
definition	definition	NN	I-NP
,	,	,	0
used	used	VBN	0
previously	previously	RB	0
in	in	IN	0
the	the	DT	0
Systolic	Systolic	NNP	B-NP
Hypertension	Hypertension	NNP	I-NP
in	in	IN	0
the	the	DT	0
Elderly	Elderly	JJ	0
Program	Program	NN	0
(	(	-LRB-	0
SHEP	SHEP	NNP	B-NP
)	)	-RRB-	0
[	[	-LRB-	0
5	5	LS	0
]	]	-RRB-	0
,	,	,	0
includes	includes	VBZ	0
"patients	"patients	CD	0
with	with	IN	0
clear-cut	clear-cut	JJ	B-NP
sign	sign	NN	I-NP
or	or	CC	0
symptom	symptom	NN	B-NP
of	of	IN	0
left	left	VBN	0
or	or	CC	0
right	right	RB	0
ventricular	ventricular	JJ	B-NP
dysfunction	dysfunction	NN	I-NP
that	that	WDT	0
cannot	cannot	RB	0
be	be	VB	0
attributed	attributed	VBN	0
to	to	TO	0
other	other	JJ	0
causes...	causes...	NN	0
"	"	''	0
The	The	DT	0
diagnosis	diagnosis	NN	0
of	of	IN	0
HF	HF	NNP	B-NP
must	must	MD	0
include	include	VB	0
at	at	IN	0
least	least	JJS	0
one	one	CD	0
of	of	IN	0
four	four	CD	0
stated	stated	JJ	0
symptom	symptom	NN	B-NP
[	[	-LRB-	0
paroxysmal	paroxysmal	NN	B-NP
nocturnal	nocturnal	JJ	I-NP
dyspnea	dyspnea	NN	I-NP
,	,	,	0
dyspnea	dyspnea	VBG	0
at	at	IN	0
rest	rest	NN	0
,	,	,	0
functional	functional	JJ	B-NP
class	class	NN	I-NP
iii	iii	NN	I-NP
new	new	JJ	I-NP
york	york	NNP	I-NP
heart	heart	NN	I-NP
classification	classification	NN	I-NP
(	(	-LRB-	0
for	for	IN	0
definition	definition	NN	0
see	see	VBP	0
Additional	Additional	JJ	B-NP
Information	Information	NNP	I-NP
,	,	,	0
Item	Item	NNP	0
1	1	CD	0
)	)	-RRB-	0
,	,	,	0
or	or	CC	0
orthopnea	orthopnea	CD	B-NP
]	]	-RRB-	0
,	,	,	0
and	and	CC	0
one	one	CD	0
of	of	IN	0
seven	seven	CD	0
stated	stated	JJ	0
signs	signs	NNS	0
(	(	-LRB-	0
rales	rales	UH	0
,	,	,	0
2+	2+	NNP	0
or	or	CC	0
greater	greater	JJR	0
ankle	ankle	JJ	B-NP
edema	edema	NN	I-NP
,	,	,	0
tachycardia	tachycardia	NN	B-NP
of	of	IN	0
120	120	CD	0
beats	beats	CD	B-NP
/	/	CD	I-NP
minute	minute	NN	I-NP
or	or	CC	0
more	more	JJR	0
after	after	IN	0
five	five	CD	0
minutes	minutes	NNS	0
at	at	IN	0
rest	rest	NN	0
,	,	,	0
cardiomegaly	cardiomegaly	VBG	0
by	by	IN	0
chest	chest	JJ	B-NP
x-ray	x-ray	NN	I-NP
,	,	,	0
hf	hf	NN	B-NP
chest	chest	JJ	I-NP
x-ray	x-ray	JJ	I-NP
characteristic	characteristic	NN	I-NP
,	,	,	0
S	S	NNP	0
3	3	CD	0
gallop	gallop	NN	0
,	,	,	0
or	or	CC	0
jugular	jugular	JJ	B-NP
venous	venous	JJ	I-NP
distention	distention	NN	I-NP
)	)	-RRB-	0
.	.	.	0
Since	Since	IN	0
lower	lower	JJR	0
extremity	extremity	JJ	B-NP
edema	edema	NN	I-NP
or	or	CC	0
exertional	exertional	JJ	B-NP
dyspnea	dyspnea	NN	I-NP
may	may	MD	0
be	be	VB	0
due	due	JJ	0
to	to	TO	0
non-cardiac	non-cardiac	JJ	B-NP
cause	cause	NN	I-NP
,	,	,	0
the	the	DT	0
presence	presence	NN	0
of	of	IN	0
either	either	RB	0
of	of	IN	0
these	these	DT	0
alone	alone	RB	0
,	,	,	0
without	without	IN	0
other	other	JJ	0
indications	indications	NNS	0
of	of	IN	0
heart	heart	NN	B-NP
failure	failure	NN	I-NP
,	,	,	0
is	is	VBZ	0
not	not	RB	0
sufficient	sufficient	JJ	0
for	for	IN	0
a	a	DT	0
diagnosis	diagnosis	NN	0
of	of	IN	0
HF	HF	NNP	B-NP
.	.	.	0
study	study	NN	B-NP
guideline	guideline	NN	I-NP
caution	caution	VBP	0
against	against	IN	0
a	a	DT	0
hasty	hasty	JJ	0
HF	HF	NNP	B-NP
diagnosis	diagnosis	NN	I-NP
in	in	IN	0
patients	patients	NNS	0
with	with	IN	0
severe	severe	JJ	0
pulmonary	pulmonary	JJ	B-NP
disease	disease	NN	I-NP
,	,	,	0
including	including	VBG	0
chronic	chronic	JJ	B-NP
obstructive	obstructive	JJ	I-NP
pulmonary	pulmonary	JJ	I-NP
disease	disease	NN	I-NP
(	(	-LRB-	0
chronic	chronic	JJ	B-NP
obstructive	obstructive	JJ	I-NP
pulmonary	pulmonary	JJ	I-NP
disease	disease	NN	I-NP
)	)	-RRB-	0
,	,	,	0
pneumonia	pneumonia	NN	0
,	,	,	0
or	or	CC	0
other	other	JJ	0
severe	severe	JJ	0
,	,	,	0
documented	documented	VBN	B-NP
lung	lung	NN	I-NP
disease	disease	NN	I-NP
.	.	.	0
baseline	baseline	NN	B-NP
characteristic	characteristic	JJ	I-NP
and	and	CC	0
chlorthalidone	chlorthalidone	NN	B-NP
medical	medical	JJ	I-NP
management	management	NN	I-NP
baseline	baseline	NN	I-NP
characteristic	characteristic	JJ	I-NP
and	and	CC	0
doxazosin	doxazosin	JJ	B-NP
participant	participant	NN	I-NP
were	were	VBD	0
compared	compared	VBN	0
.	.	.	0
These	These	DT	0
analyses	analyses	NNS	0
were	were	VBD	0
stratified	stratified	VBN	0
by	by	IN	0
HF	HF	NNP	B-NP
outcome	outcome	NN	I-NP
:	:	:	0
1	1	LS	0
)	)	-RRB-	0
fatal	fatal	JJ	0
and	and	CC	0
hospitalized	hospitalized	VBN	B-NP
HF	HF	NNP	I-NP
;	;	:	0
2	2	LS	0
)	)	-RRB-	0
treated	treated	VBN	0
,	,	,	0
non-hospitalized	non-hospitalized	NNP	B-NP
HF	HF	NNP	I-NP
;	;	:	0
and	and	CC	0
,	,	,	0
3	3	LS	0
)	)	-RRB-	0
no	no	DT	0
HF	HF	NNP	B-NP
.	.	.	0
medical	medical	JJ	B-NP
management	management	NN	I-NP
post-hf	post-hf	NN	I-NP
event	event	NN	I-NP
may	may	MD	0
provide	provide	VB	0
additional	additional	JJ	0
evidence	evidence	NN	0
of	of	IN	0
the	the	DT	0
physicians	physicians	NNS	0
'	'	POS	0
confidence	confidence	NN	0
in	in	IN	0
the	the	DT	0
HF	HF	NNP	B-NP
diagnosis	diagnosis	NN	I-NP
.	.	.	0
The	The	DT	0
open-label	open-label	JJ	B-NP
diuretic	diuretic	NN	I-NP
post-event	post-event	JJ	I-NP
use	use	NN	I-NP
,	,	,	0
ace-inhibitor	ace-inhibitor	NN	B-NP
,	,	,	0
and	and	CC	0
beta-blocker	beta-blocker	NN	B-NP
,	,	,	0
i.e.	i.e.	FW	0
,	,	,	0
hf	hf	NN	B-NP
accepted	accepted	VBD	I-NP
treatment	treatment	NN	I-NP
[	[	-LRB-	0
6	6	CD	0
7	7	CD	0
8	8	CD	0
9	9	CD	0
]	]	-RRB-	0
,	,	,	0
was	was	VBD	0
compared	compared	VBN	0
between	between	IN	0
doxazosin	doxazosin	NN	B-NP
and	and	CC	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
,	,	,	0
as	as	RB	0
was	was	VBD	0
the	the	DT	0
proportion	proportion	NN	0
in	in	IN	0
each	each	DT	0
group	group	NN	0
of	of	IN	0
those	those	DT	0
who	who	WP	0
remained	remained	VBD	0
on	on	IN	0
assigned	assigned	VBN	0
blinded	blinded	JJ	0
medication	medication	NN	0
after	after	IN	0
the	the	DT	0
event	event	NN	0
.	.	.	0
(	(	-LRB-	0
For	For	IN	0
study	study	NN	B-NP
guideline	guideline	NN	I-NP
regarding	regarding	VBG	0
the	the	DT	0
use	use	NN	0
and	and	CC	0
reporting	reporting	VBG	0
of	of	IN	0
open-label	open-label	JJ	B-NP
medicine	medicine	NN	I-NP
of	of	IN	0
the	the	DT	0
same	same	JJ	0
class	class	NN	0
as	as	IN	0
the	the	DT	0
blinded	blinded	JJ	0
drugs	drugs	NNS	0
,	,	,	0
see	see	VBP	0
Additional	Additional	JJ	B-NP
Information	Information	NNP	I-NP
,	,	,	0
Items	Items	NNP	0
2	2	CD	0
and	and	CC	0
3	3	CD	0
.	.	.	0
)	)	-RRB-	0
Ejection	Ejection	NNP	B-NP
Fraction	Fraction	NNP	I-NP
Review	Review	NNP	I-NP
A	A	NNP	0
CTC	CTC	NNP	B-NP
physician	physician	NN	I-NP
plus	plus	CC	0
non-medical	non-medical	JJ	B-NP
staff	staff	NN	I-NP
reviewed	reviewed	VBN	0
in	in	IN	0
a	a	DT	0
blinded	blinded	JJ	0
fashion	fashion	NN	0
361	361	CD	0
hospitalized	hospitalized	JJ	0
hf	hf	NN	B-NP
event	event	NN	I-NP
(	(	-LRB-	0
representing	representing	VBG	0
278	278	CD	0
participant	participant	NN	B-NP
)	)	-RRB-	0
for	for	IN	0
ejection	ejection	JJ	B-NP
fraction	fraction	NN	I-NP
data	data	NN	I-NP
:	:	:	0
looking	looking	VBG	0
for	for	IN	0
whether	whether	IN	0
an	an	DT	0
ejection	ejection	JJ	B-NP
fraction	fraction	NN	I-NP
was	was	VBD	0
measured	measured	VBN	0
,	,	,	0
the	the	DT	0
method	method	NN	B-NP
utilized	utilized	NN	I-NP
,	,	,	0
and	and	CC	0
the	the	DT	0
measurement	measurement	NN	0
.	.	.	0
Results	Results	NNS	0
,	,	,	0
tabulated	tabulated	VBG	0
by	by	IN	0
randomization	randomization	JJ	B-NP
group	group	NN	I-NP
,	,	,	0
reflected	reflected	VBD	0
data	data	NNS	0
that	that	WDT	0
had	had	VBD	0
been	been	VBN	0
collected	collected	VBN	0
up	up	RP	0
to	to	TO	0
July	July	NNP	0
,	,	,	0
1999	1999	CD	0
,	,	,	0
the	the	DT	0
time	time	NN	0
of	of	IN	0
the	the	DT	0
review	review	NN	0
.	.	.	0
case-fatality	case-fatality	NN	B-NP
rate	rate	NN	I-NP
and	and	CC	0
Causes	Causes	NNP	0
of	of	IN	0
Death	Death	NN	0
As	As	IN	0
a	a	DT	0
measure	measure	NN	0
of	of	IN	0
the	the	DT	0
diagnostic	diagnostic	JJ	B-NP
validity	validity	NN	I-NP
and	and	CC	0
severity	severity	NN	0
of	of	IN	0
HF	HF	NNP	B-NP
and	and	CC	0
comparability	comparability	NN	B-NP
between	between	IN	0
drug	drug	NN	B-NP
group	group	NN	I-NP
,	,	,	0
participant	participant	NN	B-NP
time-from-event-to-death	time-from-event-to-death	JJ	I-NP
analysis	analysis	NN	I-NP
with	with	IN	0
hospitalized	hospitalized	NN	0
or	or	CC	0
treated	treated	VBN	B-NP
HF	HF	NNP	I-NP
were	were	VBD	0
compared	compared	VBN	0
between	between	IN	0
the	the	DT	0
two	two	CD	0
groups	groups	NNS	0
.	.	.	0
Causes	Causes	NNS	0
of	of	IN	0
death	death	NN	0
of	of	IN	0
such	such	JJ	0
participant	participant	NN	B-NP
were	were	VBD	0
also	also	RB	0
compared	compared	VBN	0
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	NN	B-NP
and	and	CC	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
.	.	.	0
statistical	statistical	JJ	B-NP
analysis	analysis	NN	I-NP
Data	Data	NNP	0
were	were	VBD	0
analyzed	analyzed	VBN	0
according	according	VBG	0
to	to	TO	0
participant	participant	NN	B-NP
'	'	POS	0
randomization	randomization	JJ	B-NP
assignment	assignment	NN	I-NP
and	and	CC	0
HF	HF	NNP	B-NP
outcome	outcome	NN	I-NP
status	status	NN	I-NP
,	,	,	0
regardless	regardless	RB	0
of	of	IN	0
subsequent	subsequent	JJ	0
medication	medication	NN	B-NP
adherence	adherence	NN	I-NP
.	.	.	0
The	The	DT	0
Kaplan-Meier	Kaplan-Meier	JJ	B-NP
method	method	NN	I-NP
was	was	VBD	0
utilized	utilized	VBN	0
in	in	IN	0
calculating	calculating	VBG	0
cumulative	cumulative	JJ	B-NP
event	event	NN	I-NP
rate	rate	NN	I-NP
.	.	.	0
Descriptive	Descriptive	JJ	B-NP
statistic	statistic	NN	I-NP
by	by	IN	0
treatment	treatment	NN	B-NP
group	group	NN	I-NP
were	were	VBD	0
presented	presented	VBN	0
for	for	IN	0
baseline	baseline	NN	B-NP
characteristic	characteristic	JJ	I-NP
,	,	,	0
HF	HF	NNP	B-NP
ascertainment	ascertainment	NN	I-NP
,	,	,	0
ejection	ejection	JJ	B-NP
fraction	fraction	NN	I-NP
and	and	CC	0
use	use	NN	0
of	of	IN	0
hf	hf	NN	B-NP
medication	medication	NN	I-NP
.	.	.	0
baseline	baseline	NN	B-NP
characteristic	characteristic	JJ	I-NP
comparability	comparability	NN	I-NP
of	of	IN	0
the	the	DT	0
treatment	treatment	NN	0
and	and	CC	0
hf	hf	NN	B-NP
outcome	outcome	NN	I-NP
group	group	NN	I-NP
was	was	VBD	0
ascertained	ascertained	VBN	0
by	by	IN	0
the	the	DT	0
χ	χ	JJ	0
2test	2test	NN	0
for	for	IN	0
categorical	categorical	JJ	B-NP
variable	variable	JJ	I-NP
and	and	CC	0
standard	standard	JJ	0
normal	normal	JJ	0
(	(	-LRB-	0
z	z	LS	0
)	)	-RRB-	0
test	test	NN	0
for	for	IN	0
continuous	continuous	JJ	B-NP
variable	variable	JJ	I-NP
.	.	.	0
Results	Results	NNP	0
diagnostic	diagnostic	JJ	B-NP
criterion	criterion	NN	I-NP
heart	heart	NN	I-NP
failure	failure	NN	I-NP
The	The	DT	0
blinded	blinded	JJ	0
review	review	NN	0
by	by	IN	0
the	the	DT	0
endpoint	endpoint	NN	B-NP
Subcommittee	Subcommittee	NNP	0
of	of	IN	0
50	50	CD	0
fatal	fatal	NNS	0
or	or	CC	0
hospitalized	hospitalized	VBN	B-NP
hf	hf	NN	I-NP
event	event	NN	I-NP
from	from	IN	0
the	the	DT	0
4	4	CD	0
drug	drug	NN	B-NP
group	group	NN	I-NP
determined	determined	VBD	0
11	11	CD	0
(	(	-LRB-	0
22	22	CD	0
%	%	NN	0
)	)	-RRB-	0
to	to	TO	0
have	have	VB	0
incomplete	incomplete	JJ	0
data	data	NNS	0
for	for	IN	0
a	a	DT	0
definitive	definitive	JJ	0
review	review	NN	0
.	.	.	0
Of	Of	IN	0
the	the	DT	0
remaining	remaining	JJ	0
39	39	CD	0
,	,	,	0
33	33	CD	0
(	(	-LRB-	0
85	85	CD	0
%	%	NN	0
)	)	-RRB-	0
were	were	VBD	0
confirmed	confirmed	VBN	0
to	to	TO	0
have	have	VB	0
HF	HF	NNP	B-NP
by	by	IN	0
one	one	CD	0
or	or	CC	0
both	both	DT	0
reviewers	reviewers	NN	0
.	.	.	0
For	For	IN	0
both	both	PDT	0
the	the	DT	0
chlorthalidone	chlorthalidone	NN	B-NP
and	and	CC	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
,	,	,	0
the	the	DT	0
diagnosis	diagnosis	NN	0
of	of	IN	0
HF	HF	NNP	B-NP
was	was	VBD	0
confirmed	confirmed	VBN	0
in	in	IN	0
90	90	CD	0
%	%	NN	0
(	(	-LRB-	0
18	18	CD	0
/	/	CD	0
20	20	CD	0
)	)	-RRB-	0
.	.	.	0
baseline	baseline	NN	B-NP
characteristic	characteristic	JJ	I-NP
baseline	baseline	NN	I-NP
characteristic	characteristic	JJ	I-NP
for	for	IN	0
the	the	DT	0
doxazosin	doxazosin	NN	B-NP
and	and	CC	0
chlorthalidone	chlorthalidone	JJ	B-NP
treatment	treatment	NN	I-NP
group	group	NN	I-NP
,	,	,	0
stratified	stratified	VBG	0
for	for	IN	0
HF	HF	NNP	B-NP
status	status	NN	I-NP
,	,	,	0
are	are	VBP	0
described	described	VBN	0
in	in	IN	0
Table	Table	NNP	0
1	1	CD	0
.	.	.	0
doxazosin	doxazosin	NN	B-NP
baseline	baseline	NN	I-NP
characteristic	characteristic	JJ	I-NP
and	and	CC	0
chlorthalidone	chlorthalidone	JJ	B-NP
participant	participant	NN	I-NP
with	with	IN	0
subsequent	subsequent	JJ	0
hospitalized	hospitalized	NN	0
or	or	CC	0
fatal	fatal	JJ	B-NP
HF	HF	NNP	I-NP
were	were	VBD	0
compared	compared	VBN	0
.	.	.	0
doxazosin	doxazosin	NN	B-NP
participant	participant	NN	I-NP
with	with	IN	0
hospitalized	hospitalized	NN	0
or	or	CC	0
fatal	fatal	JJ	B-NP
HF	HF	NNP	I-NP
had	had	VBD	0
a	a	DT	0
higher	higher	JJR	0
baseline	baseline	NN	B-NP
SBP	SBP	NN	I-NP
than	than	IN	0
the	the	DT	0
chlorthalidone	chlorthalidone	JJ	B-NP
participant	participant	NN	I-NP
(	(	-LRB-	0
150.1	150.1	FW	0
vs.	vs.	FW	0
147.8	147.8	FW	0
mm	mm	NN	B-NP
Hg	Hg	NNP	I-NP
at	at	IN	0
the	the	DT	0
randomization	randomization	JJ	B-NP
visit	visit	NN	I-NP
)	)	-RRB-	0
.	.	.	0
More	More	RBR	0
doxazosin	doxazosin	JJ	B-NP
participant	participant	NN	I-NP
had	had	VBD	0
left	left	JJ	B-NP
ventricular	ventricular	JJ	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
hypertrophy	hypertrophy	NN	I-NP
by	by	IN	0
ECG	ECG	NNP	B-NP
(	(	-LRB-	0
22.3	22.3	CD	0
%	%	NN	0
vs.	vs.	IN	0
20.5	20.5	CD	0
%	%	NN	0
of	of	IN	0
chlorthalidone	chlorthalidone	JJ	B-NP
participant	participant	NN	I-NP
)	)	-RRB-	0
;	;	:	0
slightly	slightly	RB	0
more	more	JJR	0
chlorthalidone	chlorthalidone	NN	B-NP
than	than	IN	0
doxazosin	doxazosin	JJ	B-NP
participant	participant	NN	I-NP
had	had	VBD	0
left	left	JJ	B-NP
ventricular	ventricular	JJ	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
		NN	I-NP
hypertrophy	hypertrophy	NN	I-NP
by	by	IN	0
echocardiogram	echocardiogram	NN	B-NP
.	.	.	0
Several	Several	JJ	0
eligibility	eligibility	JJ	B-NP
risk	risk	NN	I-NP
factor	factor	NN	I-NP
,	,	,	0
including	including	VBG	0
previous	previous	JJ	0
MIs	MIs	JJ	0
or	or	CC	0
strokes	strokes	NNS	0
,	,	,	0
coronary	coronary	JJ	B-NP
revascularization	revascularization	JJ	I-NP
procedure	procedure	NN	I-NP
,	,	,	0
other	other	JJ	0
atherosclerotic	atherosclerotic	JJ	B-NP
cardiovascular	cardiovascular	JJ	I-NP
disease	disease	NN	I-NP
(	(	-LRB-	0
atherosclerotic	atherosclerotic	NN	B-NP
cardiovascular	cardiovascular	JJ	I-NP
disease	disease	NN	I-NP
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
st-t	st-t	NN	B-NP
wave	wave	NN	I-NP
change	change	NN	I-NP
,	,	,	0
were	were	VBD	0
reported	reported	VBN	0
more	more	RBR	0
often	often	RB	0
in	in	IN	0
chlorthalidone	chlorthalidone	NN	B-NP
than	than	IN	0
in	in	IN	0
doxazosin	doxazosin	JJ	B-NP
participant	participant	NN	I-NP
,	,	,	0
though	though	IN	0
the	the	DT	0
differences	differences	NNS	0
were	were	VBD	0
not	not	RB	0
significant	significant	JJ	0
.	.	.	0
Chlorthalidone	Chlorthalidone	NNP	B-NP
and	and	CC	0
doxazosin	doxazosin	JJ	B-NP
participant	participant	NN	I-NP
with	with	IN	0
hospitalized	hospitalized	NN	0
or	or	CC	0
fatal	fatal	JJ	B-NP
HF	HF	NNP	I-NP
had	had	VBD	0
similar	similar	JJ	0
pre-trial	pre-trial	JJ	B-NP
antihypertensive	antihypertensive	JJ	I-NP
treatment	treatment	NN	I-NP
duration	duration	NN	I-NP
.	.	.	0
None	None	NN	0
of	of	IN	0
these	these	DT	0
differences	differences	NNS	0
was	was	VBD	0
significant	significant	JJ	0
at	at	IN	0
P	P	NNP	0
<	<	SYM	0
.05	.05	NNP	0
.	.	.	0
participant	participant	NN	B-NP
with	with	IN	0
hf	hf	NN	B-NP
event	event	NN	I-NP
displayed	displayed	VBD	0
higher	higher	JJR	0
rates	rates	NNS	0
of	of	IN	0
most	most	RBS	0
cardiovascular	cardiovascular	JJ	B-NP
risk	risk	NN	I-NP
factor	factor	NN	I-NP
compared	compared	VBN	0
to	to	TO	0
those	those	DT	0
without	without	IN	0
hf	hf	NN	B-NP
event	event	NN	I-NP
.	.	.	0
Approximately	Approximately	RB	0
35-36	35-36	CD	0
%	%	NN	0
of	of	IN	0
chlorthalidone	chlorthalidone	NN	B-NP
and	and	CC	0
doxazosin	doxazosin	JJ	B-NP
participant	participant	NN	I-NP
with	with	IN	0
fatal	fatal	JJ	0
or	or	CC	0
hospitalized	hospitalized	VBN	B-NP
HF	HF	NNP	I-NP
had	had	VBD	0
reported	reported	VBN	0
prior	prior	JJ	0
MI	MI	NNP	0
or	or	CC	0
stroke	stroke	NN	0
as	as	IN	0
baseline	baseline	JJ	B-NP
eligibility	eligibility	JJ	I-NP
risk	risk	NN	I-NP
factor	factor	NN	I-NP
,	,	,	0
compared	compared	VBN	0
to	to	TO	0
22-23	22-23	CD	0
%	%	NN	0
of	of	IN	0
those	those	DT	0
without	without	IN	0
HF	HF	NNP	B-NP
(	(	-LRB-	0
P	P	NNP	0
<	<	SYM	0
.001	.001	NNP	0
)	)	-RRB-	0
.	.	.	0
participant	participant	NN	B-NP
with	with	IN	0
hospitalized	hospitalized	VBN	B-NP
/	/	NN	I-NP
fatal	fatal	JJ	I-NP
HF	HF	NNP	I-NP
had	had	VBD	0
significantly	significantly	RB	0
higher	higher	JJR	0
rates	rates	NNS	0
of	of	IN	0
pre-randomization	pre-randomization	NN	B-NP
coronary	coronary	JJ	I-NP
artery	artery	NN	I-NP
bypass	bypass	NNS	I-NP
graft	graft	NN	I-NP
(	(	-LRB-	0
CABGs	CABGs	NNP	B-NP
)	)	-RRB-	0
and	and	CC	0
coronary	coronary	JJ	B-NP
angioplasty	angioplasty	NN	I-NP
(	(	-LRB-	0
19-23	19-23	NNP	0
%	%	NN	0
of	of	IN	0
those	those	DT	0
with	with	IN	0
HF	HF	NNP	B-NP
vs.	vs.	CC	0
13	13	CD	0
%	%	NN	0
of	of	IN	0
those	those	DT	0
without	without	NN	0
;	;	:	0
P	P	NNP	0
<	<	SYM	0
.001	.001	NNP	0
)	)	-RRB-	0
and	and	CC	0
other	other	JJ	0
atherosclerotic	atherosclerotic	JJ	B-NP
cardiovascular	cardiovascular	JJ	I-NP
disease	disease	NN	I-NP
(	(	-LRB-	0
atherosclerotic	atherosclerotic	NN	B-NP
cardiovascular	cardiovascular	JJ	I-NP
disease	disease	NN	I-NP
)	)	-RRB-	0
(	(	-LRB-	0
29-33	29-33	NNP	0
%	%	NN	0
of	of	IN	0
those	those	DT	0
with	with	IN	0
HF	HF	NNP	0
vs.	vs.	FW	0
23-25	23-25	FW	0
%	%	NN	0
of	of	IN	0
those	those	DT	0
without	without	NN	0
;	;	:	0
P	P	NNP	0
<	<	SYM	0
.001	.001	NNP	0
)	)	-RRB-	0
.	.	.	0
Diabetes	Diabetes	NN	0
as	as	IN	0
a	a	DT	0
baseline	baseline	NN	0
risk	risk	NN	0
factor	factor	NN	0
occurred	occurred	VBD	0
more	more	RBR	0
frequently	frequently	RB	0
in	in	IN	0
those	those	DT	0
with	with	IN	0
HF	HF	NNP	0
:	:	:	0
47-48	47-48	CD	0
%	%	NN	0
in	in	IN	0
those	those	DT	0
with	with	IN	0
HF	HF	NNP	0
,	,	,	0
35-36	35-36	CD	0
%	%	NN	0
in	in	IN	0
those	those	DT	0
without	without	IN	0
(	(	-LRB-	0
P	P	NNP	0
<	<	SYM	0
.001	.001	NNP	0
)	)	-RRB-	0
.	.	.	0
Left	Left	VBN	B-NP
ventricular	ventricular	JJ	I-NP
hypertrophy	hypertrophy	NN	I-NP
(	(	-LRB-	0
left	left	JJ	B-NP
ventricular	ventricular	JJ	I-NP
hypertrophy	hypertrophy	NN	I-NP
)	)	-RRB-	0
by	by	IN	0
ECG	ECG	NNP	0
was	was	VBD	0
a	a	DT	0
risk	risk	NN	0
factor	factor	NN	0
in	in	IN	0
21-22	21-22	CD	0
%	%	NN	0
of	of	IN	0
those	those	DT	0
who	who	WP	0
later	later	RB	0
developed	developed	VBN	0
HF	HF	NNP	0
,	,	,	0
compared	compared	VBN	0
with	with	IN	0
16	16	CD	0
%	%	NN	0
of	of	IN	0
those	those	DT	0
in	in	IN	0
each	each	DT	0
group	group	NN	0
who	who	WP	0
did	did	VBD	0
not	not	RB	0
develop	develop	VB	0
HF	HF	NNP	0
(	(	-LRB-	0
P	P	NNP	0
<	<	SYM	0
.001	.001	NNP	0
)	)	-RRB-	0
.	.	.	0
Baseline	Baseline	JJ	B-NP
pulse	pulse	NN	I-NP
pressure	pressure	NN	I-NP
(	(	-LRB-	0
pulse	pulse	NN	B-NP
pressure	pressure	NN	I-NP
)	)	-RRB-	0
showed	showed	VBD	0
some	some	DT	0
variation	variation	NN	0
between	between	IN	0
participant	participant	NN	B-NP
who	who	WP	0
did	did	VBD	0
and	and	CC	0
did	did	VBD	0
not	not	RB	0
develop	develop	VB	0
HF	HF	NNP	B-NP
.	.	.	0
For	For	IN	0
participant	participant	NN	B-NP
with	with	IN	0
subsequent	subsequent	JJ	0
hospitalization	hospitalization	NN	B-NP
or	or	CC	0
death	death	NN	0
from	from	IN	0
HF	HF	NNP	B-NP
,	,	,	0
pulse	pulse	NN	B-NP
pressure	pressure	NN	I-NP
was	was	VBD	0
67	67	CD	0
and	and	CC	0
68	68	CD	0
chlorthalidone	chlorthalidone	NN	B-NP
mm	mm	CD	I-NP
hg	hg	NN	I-NP
and	and	CC	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
,	,	,	0
respectively	respectively	RB	0
.	.	.	0
Treated	Treated	NNP	0
,	,	,	0
non-hospitalized	non-hospitalized	JJ	B-NP
participant	participant	NN	I-NP
showed	showed	VBD	0
a	a	DT	0
lower	lower	JJR	0
mean	mean	JJ	0
baseline	baseline	NN	B-NP
PP	PP	NN	I-NP
of	of	IN	0
65	65	CD	0
(	(	-LRB-	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
)	)	-RRB-	0
and	and	CC	0
64	64	CD	0
mm	mm	JJ	B-NP
Hg	Hg	NNP	I-NP
(	(	-LRB-	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
)	)	-RRB-	0
,	,	,	0
and	and	CC	0
an	an	DT	0
even	even	RB	0
lower	lower	RBR	0
mean	mean	JJ	0
pulse	pulse	NN	B-NP
pressure	pressure	NN	I-NP
in	in	IN	0
those	those	DT	0
without	without	IN	0
HF	HF	NNP	B-NP
(	(	-LRB-	0
62	62	CD	0
mm	mm	CD	B-NP
Hg	Hg	NN	I-NP
in	in	IN	0
each	each	DT	0
group	group	NN	0
)	)	-RRB-	0
.	.	.	0
Medical	Medical	NNP	0
Management	Management	NNP	0
Table	Table	NNP	0
2presents	2presents	NNP	0
post-event	post-event	JJ	0
participant	participant	NN	B-NP
pharmacologic	pharmacologic	JJ	I-NP
treatment	treatment	NN	I-NP
with	with	IN	0
HF	HF	NNP	B-NP
and	and	CC	0
participant	participant	NN	B-NP
antihypertensive	antihypertensive	JJ	I-NP
treatment	treatment	NN	I-NP
without	without	IN	0
HF	HF	NNP	B-NP
.	.	.	0
Following	Following	VBG	0
hf	hf	NN	B-NP
hospitalization	hospitalization	NN	I-NP
,	,	,	0
36	36	CD	0
%	%	NN	0
(	(	-LRB-	0
83	83	CD	0
/	/	CD	0
232	232	CD	0
)	)	-RRB-	0
of	of	IN	0
chlorthalidone	chlorthalidone	JJ	B-NP
participant	participant	NN	I-NP
and	and	CC	0
45	45	CD	0
%	%	NN	0
(	(	-LRB-	0
126	126	CD	0
/	/	CD	0
281	281	CD	0
)	)	-RRB-	0
of	of	IN	0
doxazosin	doxazosin	JJ	B-NP
participant	participant	NN	I-NP
remained	remained	VBD	0
on	on	IN	0
their	their	PRP$	0
blinded	blinded	JJ	0
medications	medications	NN	0
.	.	.	0
Percentages	Percentages	NNS	0
of	of	IN	0
participant	participant	NN	B-NP
on	on	IN	0
open-label	open-label	JJ	B-NP
diuretic	diuretic	NN	I-NP
and	and	CC	0
ace-inhibitor	ace-inhibitor	NN	B-NP
were	were	VBD	0
similar	similar	JJ	0
following	following	VBG	0
the	the	DT	0
event	event	NN	0
:	:	:	0
58	58	CD	0
%	%	NN	0
(	(	-LRB-	0
135	135	CD	0
/	/	CD	0
232	232	CD	0
)	)	-RRB-	0
of	of	IN	0
chlorthalidone	chlorthalidone	JJ	B-NP
participant	participant	NN	I-NP
and	and	CC	0
64	64	CD	0
%	%	NN	0
(	(	-LRB-	0
180	180	CD	0
/	/	CD	0
281	281	CD	0
)	)	-RRB-	0
of	of	IN	0
doxazosin	doxazosin	JJ	B-NP
participant	participant	NN	I-NP
were	were	VBD	0
prescribed	prescribed	VBN	B-NP
open-label	open-label	JJ	I-NP
diuretic	diuretic	NN	I-NP
;	;	:	0
39	39	CD	0
%	%	NN	0
(	(	-LRB-	0
90	90	CD	0
/	/	CD	0
232	232	CD	0
)	)	-RRB-	0
of	of	IN	0
chlorthalidone	chlorthalidone	JJ	B-NP
participant	participant	NN	I-NP
and	and	CC	0
41	41	CD	0
%	%	NN	0
(	(	-LRB-	0
114	114	CD	0
/	/	CD	0
281	281	CD	0
)	)	-RRB-	0
of	of	IN	0
doxazosin	doxazosin	JJ	B-NP
participant	participant	NN	I-NP
were	were	VBD	0
prescribed	prescribed	VBN	B-NP
open-label	open-label	JJ	I-NP
ace-inhibitor	ace-inhibitor	NN	I-NP
.	.	.	0
beta-blocker	beta-blocker	NN	B-NP
were	were	VBD	0
prescribed	prescribed	VBN	0
for	for	IN	0
14	14	CD	0
%	%	NN	0
of	of	IN	0
each	each	DT	0
group	group	NN	0
following	following	VBG	0
the	the	DT	0
event	event	NN	0
,	,	,	0
which	which	WDT	0
was	was	VBD	0
actually	actually	RB	0
somewhat	somewhat	RB	0
less	less	JJR	0
than	than	IN	0
for	for	IN	0
participant	participant	NN	B-NP
who	who	WP	0
did	did	VBD	0
not	not	RB	0
develop	develop	VB	0
HF	HF	NNP	B-NP
.	.	.	0
Three-quarters	Three-quarters	NNS	0
of	of	IN	0
hospitalized	hospitalized	JJ	0
hf	hf	NN	B-NP
participant	participant	NN	I-NP
in	in	IN	0
each	each	DT	0
group	group	NN	0
(	(	-LRB-	0
169	169	CD	0
/	/	CD	0
232	232	CD	0
in	in	IN	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
,	,	,	0
210	210	CD	0
/	/	CD	0
281	281	CD	0
in	in	IN	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
)	)	-RRB-	0
received	received	VBD	0
at	at	IN	0
least	least	JJS	0
one	one	CD	0
of	of	IN	0
the	the	DT	0
three	three	CD	0
medications	medications	NNS	0
(	(	-LRB-	0
diuretic	diuretic	UH	B-NP
,	,	,	0
ACE-inhibitor	ACE-inhibitor	NNP	B-NP
,	,	,	0
or	or	CC	0
beta-blocker	beta-blocker	NN	B-NP
)	)	-RRB-	0
post-hospitalization	post-hospitalization	JJ	B-NP
.	.	.	0
Among	Among	IN	0
participant	participant	NN	B-NP
treated	treated	VBN	0
but	but	CC	0
not	not	RB	0
hospitalized	hospitalized	VBN	0
for	for	IN	0
HF	HF	NNP	B-NP
,	,	,	0
58	58	CD	0
%	%	NN	0
(	(	-LRB-	0
54	54	CD	0
/	/	CD	0
93	93	CD	0
)	)	-RRB-	0
of	of	IN	0
the	the	DT	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
and	and	CC	0
64	64	CD	0
%	%	NN	0
(	(	-LRB-	0
93	93	CD	0
/	/	CD	0
145	145	CD	0
)	)	-RRB-	0
of	of	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
remained	remained	VBD	0
on	on	IN	0
their	their	PRP$	0
blinded	blinded	JJ	0
medication	medication	NN	0
.	.	.	0
Over	Over	IN	0
60	60	CD	0
%	%	NN	0
of	of	IN	0
participant	participant	NN	B-NP
in	in	IN	0
each	each	DT	0
group	group	NN	0
were	were	VBD	0
prescribed	prescribed	VBN	B-NP
open-label	open-label	JJ	I-NP
diuretic	diuretic	NN	I-NP
and	and	CC	0
over	over	IN	0
30	30	CD	0
%	%	NN	0
received	received	VBD	B-NP
ace-inhibitor	ace-inhibitor	NN	I-NP
.	.	.	0
Open-label	Open-label	JJ	B-NP
beta-blocker	beta-blocker	NN	I-NP
use	use	NN	I-NP
post-event	post-event	NN	I-NP
occurred	occurred	VBD	0
in	in	IN	0
19	19	CD	0
%	%	NN	0
(	(	-LRB-	0
18	18	CD	0
/	/	CD	0
93	93	CD	0
)	)	-RRB-	0
of	of	IN	0
the	the	DT	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
and	and	CC	0
22	22	CD	0
%	%	NN	0
(	(	-LRB-	0
32	32	CD	0
/	/	CD	0
145	145	CD	0
)	)	-RRB-	0
of	of	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
,	,	,	0
approximately	approximately	RB	0
the	the	DT	0
same	same	JJ	0
frequency	frequency	NN	0
as	as	IN	0
in	in	IN	0
participant	participant	NN	B-NP
without	without	IN	0
HF	HF	NNP	B-NP
.	.	.	0
In	In	IN	0
both	both	DT	0
treatment	treatment	NN	B-NP
group	group	NN	I-NP
,	,	,	0
a	a	DT	0
diuretic	diuretic	NN	B-NP
,	,	,	0
ACE-inhibitor	ACE-inhibitor	JJ	B-NP
or	or	CC	0
beta-blocker	beta-blocker	NN	B-NP
was	was	VBD	0
prescribed	prescribed	VBN	0
for	for	IN	0
over	over	IN	0
75	75	CD	0
%	%	NN	0
of	of	IN	0
these	these	DT	0
participant	participant	NN	B-NP
(	(	-LRB-	0
72	72	CD	0
/	/	CD	0
93	93	CD	0
in	in	IN	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
,	,	,	0
119	119	CD	0
/	/	CD	0
145	145	CD	0
in	in	IN	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
)	)	-RRB-	0
.	.	.	0
Ejection	Ejection	NNP	0
Fraction	Fraction	NNP	0
Review	Review	NNP	0
Table	Table	NNP	0
3displays	3displays	CD	0
the	the	DT	0
ejection	ejection	JJ	B-NP
fraction	fraction	NN	I-NP
data	data	NN	I-NP
.	.	.	0
About	About	IN	0
half	half	NN	0
(	(	-LRB-	0
178	178	CD	0
/	/	CD	0
361	361	CD	0
)	)	-RRB-	0
of	of	IN	0
mentioned	mentioned	JJ	B-NP
ejection	ejection	NN	I-NP
fraction	fraction	NN	I-NP
reviewed	reviewed	VBN	I-NP
discharge	discharge	NN	I-NP
summary	summary	JJ	I-NP
measured	measured	VBN	0
during	during	IN	0
hospitalization	hospitalization	NN	B-NP
,	,	,	0
two-thirds	two-thirds	NN	B-NP
(	(	-LRB-	0
116	116	CD	0
/	/	CD	0
169	169	CD	0
)	)	-RRB-	0
of	of	IN	0
which	which	WDT	0
had	had	VBD	0
quantitative	quantitative	JJ	B-NP
measurement	measurement	NN	I-NP
reported	reported	VBD	0
in	in	IN	0
the	the	DT	0
discharge	discharge	NN	B-NP
summary	summary	JJ	I-NP
(	(	-LRB-	0
data	data	NNS	0
not	not	RB	0
given	given	VBN	0
)	)	-RRB-	0
.	.	.	0
Considering	Considering	VBG	0
only	only	RB	0
the	the	DT	0
earliest	earliest	JJS	0
ejection	ejection	JJ	B-NP
fraction	fraction	NN	I-NP
information	information	NN	I-NP
ascertained	ascertained	NN	I-NP
for	for	IN	0
each	each	DT	0
HF	HF	NNP	B-NP
participant	participant	NN	I-NP
,	,	,	0
63	63	CD	0
%	%	NN	0
(	(	-LRB-	0
29	29	CD	0
/	/	CD	0
46	46	CD	0
)	)	-RRB-	0
of	of	IN	0
the	the	DT	0
chlorthalidone	chlorthalidone	NN	B-NP
and	and	CC	0
70	70	CD	0
%	%	NN	0
(	(	-LRB-	0
41	41	CD	0
/	/	CD	0
59	59	CD	0
)	)	-RRB-	0
of	of	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
participant	participant	NN	I-NP
had	had	VBD	0
ejection	ejection	JJ	B-NP
fraction	fraction	NN	I-NP
at	at	IN	0
or	or	CC	0
below	below	IN	0
40	40	CD	0
%	%	NN	0
.	.	.	0
Just	Just	RB	0
under	under	IN	0
half	half	NN	0
(	(	-LRB-	0
27	27	CD	0
/	/	CD	0
59	59	CD	0
)	)	-RRB-	0
of	of	IN	0
the	the	DT	0
ejection	ejection	JJ	B-NP
fraction	fraction	NN	I-NP
reported	reported	VBD	0
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
were	were	VBD	0
at	at	IN	0
or	or	CC	0
below	below	IN	0
30	30	CD	0
%	%	NN	0
,	,	,	0
compared	compared	VBN	0
with	with	IN	0
one	one	CD	0
third	third	JJ	0
(	(	-LRB-	0
15	15	CD	0
/	/	CD	0
46	46	CD	0
)	)	-RRB-	0
in	in	IN	0
the	the	DT	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
.	.	.	0
ejection	ejection	JJ	B-NP
fraction	fraction	NN	I-NP
two-thirds	two-thirds	NN	I-NP
were	were	VBD	0
obtained	obtained	VBN	0
by	by	IN	0
echocardiogram	echocardiogram	NN	B-NP
,	,	,	0
though	though	IN	0
catheterization	catheterization	NN	B-NP
accounted	accounted	VBD	0
for	for	IN	0
a	a	DT	0
larger	larger	JJR	0
percentage	percentage	NN	0
of	of	IN	0
results	results	NNS	0
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
than	than	IN	0
in	in	IN	0
the	the	DT	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
(	(	-LRB-	0
36	36	CD	0
%	%	NN	0
vs.	vs.	IN	0
24	24	CD	0
%	%	NN	0
)	)	-RRB-	0
.	.	.	0
Causes	Causes	NNS	0
of	of	IN	0
Death	Death	NNP	0
and	and	CC	0
2-Year	2-Year	NNP	0
Case-Fatality	Case-Fatality	NNP	0
Causes	Causes	NNP	0
of	of	IN	0
death	death	NN	0
of	of	IN	0
participant	participant	NN	B-NP
with	with	IN	0
previous	previous	JJ	0
HF	HF	NNP	B-NP
hospitalization	hospitalization	NN	I-NP
were	were	VBD	0
distributed	distributed	VBN	0
similarly	similarly	RB	0
in	in	IN	0
the	the	DT	0
two	two	CD	0
groups	groups	NNS	0
,	,	,	0
with	with	IN	0
slight	slight	JJ	0
variations	variations	NNS	0
.	.	.	0
HF	HF	NNP	B-NP
accounted	accounted	VBD	0
for	for	IN	0
21.2	21.2	CD	0
%	%	NN	0
(	(	-LRB-	0
11	11	CD	0
/	/	CD	0
52	52	CD	0
)	)	-RRB-	0
of	of	IN	0
the	the	DT	0
deaths	deaths	NNS	0
among	among	IN	0
chlorthalidone	chlorthalidone	JJ	B-NP
participant	participant	NN	I-NP
and	and	CC	0
17.1	17.1	CD	0
%	%	NN	0
(	(	-LRB-	0
12	12	CD	0
/	/	CD	0
70	70	CD	0
)	)	-RRB-	0
of	of	IN	0
the	the	DT	0
deaths	deaths	NNS	0
among	among	IN	0
doxazosin	doxazosin	JJ	B-NP
participant	participant	NN	I-NP
.	.	.	0
Over	Over	IN	0
half	half	NN	0
of	of	IN	0
the	the	DT	0
deaths	deaths	NNS	0
in	in	IN	0
each	each	DT	0
group	group	NN	0
(	(	-LRB-	0
29	29	CD	0
/	/	CD	0
52	52	CD	0
in	in	IN	0
the	the	DT	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
;	;	:	0
43	43	CD	0
/	/	CD	0
70	70	CD	0
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
)	)	-RRB-	0
were	were	VBD	0
due	due	JJ	0
to	to	TO	0
cardiovascular	cardiovascular	JJ	B-NP
event	event	NN	I-NP
.	.	.	0
Fifteen	Fifteen	JJ	0
percent	percent	NN	0
(	(	-LRB-	0
8	8	CD	0
/	/	CD	0
52	52	CD	0
)	)	-RRB-	0
of	of	IN	0
deaths	deaths	NNS	0
in	in	IN	0
the	the	DT	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
were	were	VBD	0
attributed	attributed	VBN	0
to	to	TO	0
cancer	cancer	NN	0
,	,	,	0
compared	compared	VBN	0
to	to	TO	0
9	9	CD	0
%	%	NN	0
(	(	-LRB-	0
6	6	CD	0
/	/	CD	0
70	70	CD	0
)	)	-RRB-	0
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
(	(	-LRB-	0
Table	Table	NNP	0
4	4	CD	0
)	)	-RRB-	0
.	.	.	0
participant	participant	NN	B-NP
case-fatality	case-fatality	NN	I-NP
with	with	IN	0
hospitalized	hospitalized	JJ	0
hf	hf	NN	B-NP
event	event	NN	I-NP
showed	showed	VBD	0
no	no	DT	0
significant	significant	JJ	0
differences	differences	NNS	0
(	(	-LRB-	0
RR	RR	NNP	B-NP
0.96	0.96	NNP	0
,	,	,	0
95	95	CD	0
%	%	NN	0
CI	CI	NNP	0
,	,	,	0
0.67-1.38	0.67-1.38	NNP	0
,	,	,	0
P	P	NN	0
=	=	SYM	0
0.83	0.83	CD	0
)	)	-RRB-	0
between	between	IN	0
the	the	DT	0
two	two	CD	0
treatment	treatment	NN	B-NP
group	group	NN	I-NP
(	(	-LRB-	0
Figure	Figure	NNP	0
1	1	CD	0
)	)	-RRB-	0
.	.	.	0
Among	Among	IN	0
participant	participant	NN	B-NP
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
treatment	treatment	NN	I-NP
group	group	NN	I-NP
who	who	WP	0
had	had	VBD	0
been	been	VBN	0
previously	previously	RB	0
hospitalized	hospitalized	VBN	0
for	for	IN	0
HF	HF	NNP	B-NP
,	,	,	0
22.1	22.1	CD	0
%	%	NN	0
(	(	-LRB-	0
70	70	CD	0
/	/	CD	0
317	317	CD	0
)	)	-RRB-	0
subsequently	subsequently	RB	0
died	died	VBD	0
,	,	,	0
compared	compared	VBN	0
to	to	TO	0
18.6	18.6	CD	0
%	%	NN	0
(	(	-LRB-	0
52	52	CD	0
/	/	CD	0
280	280	CD	0
)	)	-RRB-	0
of	of	IN	0
those	those	DT	0
in	in	IN	0
the	the	DT	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
(	(	-LRB-	0
Table	Table	NNP	0
4	4	CD	0
)	)	-RRB-	0
.	.	.	0
As	As	RB	0
previously	previously	RB	0
reported	reported	VBN	0
,	,	,	0
all-cause	all-cause	JJ	0
mortality	mortality	NN	0
did	did	VBD	0
not	not	RB	0
significantly	significantly	RB	0
differ	differ	VB	0
in	in	IN	0
the	the	DT	0
two	two	CD	0
treatment	treatment	NN	0
groups	groups	NNS	0
(	(	-LRB-	0
RR	RR	NNP	0
1.03	1.03	CD	0
,	,	,	0
95	95	CD	0
%	%	NN	0
CI	CI	NNP	0
0.90-1.15	0.90-1.15	NNP	0
,	,	,	0
P	P	NN	0
=	=	SYM	0
0.56	0.56	CD	0
)	)	-RRB-	0
[	[	-LRB-	0
2	2	LS	0
]	]	-RRB-	0
.	.	.	0
Discussion	Discussion	NN	0
The	The	DT	0
finding	finding	NN	0
of	of	IN	0
significantly	significantly	RB	0
increased	increased	VBN	B-NP
hf	hf	NN	I-NP
event	event	NN	I-NP
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
compared	compared	VBN	0
with	with	IN	0
the	the	DT	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
created	created	VBD	0
a	a	DT	0
dilemma	dilemma	NN	0
for	for	IN	0
ALLHAT	ALLHAT	NNP	B-NP
.	.	.	0
Since	Since	IN	0
the	the	DT	0
trial	trial	NN	0
was	was	VBD	0
not	not	RB	0
designed	designed	VBN	0
to	to	TO	0
focus	focus	VB	0
on	on	IN	0
HF	HF	NNP	B-NP
,	,	,	0
a	a	DT	0
component	component	NN	0
of	of	IN	0
a	a	DT	0
secondary	secondary	JJ	B-NP
endpoint	endpoint	NN	I-NP
,	,	,	0
the	the	DT	0
validity	validity	NN	0
of	of	IN	0
reported	reported	VBN	B-NP
hf	hf	NN	I-NP
event	event	NN	I-NP
became	became	VBD	0
an	an	DT	0
issue	issue	NN	0
.	.	.	0
In	In	IN	0
this	this	DT	0
paper	paper	NN	0
,	,	,	0
we	we	PRP	0
have	have	VBP	0
described	described	VBN	0
several	several	JJ	0
analyses	analyses	NNS	0
to	to	TO	0
address	address	VB	0
this	this	DT	0
concern	concern	NN	0
.	.	.	0
As	As	RB	0
previously	previously	RB	0
reported	reported	VBN	0
,	,	,	0
lost-to-follow-up	lost-to-follow-up	JJ	B-NP
and	and	CC	0
event	event	NN	B-NP
documentation	documentation	NN	I-NP
were	were	VBD	0
similar	similar	JJ	0
in	in	IN	0
the	the	DT	0
two	two	CD	0
treatment	treatment	NN	B-NP
group	group	NN	I-NP
[	[	-LRB-	0
2	2	LS	0
]	]	-RRB-	0
.	.	.	0
Steps	Steps	NNS	0
employed	employed	VBN	0
to	to	TO	0
validate	validate	VB	0
the	the	DT	0
HF	HF	NNP	B-NP
outcome	outcome	NN	I-NP
in	in	IN	0
these	these	DT	0
treatment	treatment	NN	B-NP
group	group	NN	I-NP
confirmed	confirmed	VBD	0
the	the	DT	0
consistency	consistency	NN	0
of	of	IN	0
HF	HF	NNP	B-NP
event	event	NN	I-NP
reporting	reporting	NN	I-NP
.	.	.	0
participant	participant	NN	B-NP
in	in	IN	0
the	the	DT	0
two	two	CD	0
drug	drug	NN	B-NP
group	group	NN	I-NP
had	had	VBD	0
similar	similar	JJ	0
baseline	baseline	NN	B-NP
characteristic	characteristic	JJ	I-NP
when	when	WRB	0
stratified	stratified	NNS	0
by	by	IN	0
HF	HF	NNP	B-NP
status	status	NN	I-NP
.	.	.	0
The	The	DT	0
differences	differences	NNS	0
in	in	IN	0
eligibility	eligibility	JJ	B-NP
risk	risk	NN	I-NP
factor	factor	NN	I-NP
between	between	IN	0
those	those	DT	0
participant	participant	NN	B-NP
with	with	IN	0
HF	HF	NNP	B-NP
and	and	CC	0
those	those	DT	0
without	without	NN	0
is	is	VBZ	0
not	not	RB	0
surprising	surprising	JJ	0
:	:	:	0
larger	larger	JJR	0
percentages	percentages	NNS	0
of	of	IN	0
those	those	DT	0
with	with	IN	0
HF	HF	NNP	B-NP
had	had	VBD	0
a	a	DT	0
history	history	NN	0
of	of	IN	0
MI	MI	NNP	0
,	,	,	0
stroke	stroke	NN	0
,	,	,	0
CABG	CABG	NNP	B-NP
,	,	,	0
angioplasty	angioplasty	NN	0
,	,	,	0
other	other	JJ	0
atherosclerotic	atherosclerotic	JJ	B-NP
cardiovascular	cardiovascular	JJ	I-NP
disease	disease	NN	I-NP
(	(	-LRB-	0
atherosclerotic	atherosclerotic	NN	B-NP
cardiovascular	cardiovascular	JJ	I-NP
disease	disease	NN	I-NP
)	)	-RRB-	0
,	,	,	0
diabetes	diabetes	NN	0
,	,	,	0
low	low	JJ	0
hdl	hdl	NN	B-NP
level	level	JJ	I-NP
and	and	CC	0
ecg	ecg	NN	B-NP
abnormality	abnormality	NN	I-NP
.	.	.	0
Nonetheless	Nonetheless	RB	0
,	,	,	0
these	these	DT	0
eligibility	eligibility	JJ	B-NP
factor	factor	NN	I-NP
were	were	VBD	0
not	not	RB	0
substantially	substantially	RB	0
different	different	JJ	0
between	between	IN	0
chlorthalidone	chlorthalidone	NN	B-NP
and	and	CC	0
doxazosin	doxazosin	JJ	B-NP
participant	participant	NN	I-NP
with	with	IN	0
HF	HF	NNP	B-NP
.	.	.	0
pharmacologic	pharmacologic	JJ	B-NP
management	management	NN	I-NP
post-diagnosis	post-diagnosis	NN	I-NP
of	of	IN	0
patients	patients	NNS	0
is	is	VBZ	0
one	one	CD	0
measure	measure	NN	0
of	of	IN	0
the	the	DT	0
strength	strength	NN	0
of	of	IN	0
physicians	physicians	NNS	0
'	'	POS	0
confidence	confidence	NN	0
in	in	IN	0
the	the	DT	0
hf	hf	NN	B-NP
diagnosis	diagnosis	NN	I-NP
.	.	.	0
open-label	open-label	NN	B-NP
diuretic	diuretic	NN	I-NP
,	,	,	0
ace-inhibitor	ace-inhibitor	NN	B-NP
and	and	CC	0
beta-blocker	beta-blocker	NN	B-NP
,	,	,	0
all	all	DT	0
recognized	recognized	JJ	0
treatments	treatments	NNS	0
for	for	IN	0
HF	HF	NNP	B-NP
,	,	,	0
were	were	VBD	0
prescribed	prescribed	VBN	0
similarly	similarly	RB	0
for	for	IN	0
the	the	DT	0
chlorthalidone	chlorthalidone	NN	B-NP
and	and	CC	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
,	,	,	0
suggesting	suggesting	VBG	0
similar	similar	JJ	0
assessment	assessment	NN	0
of	of	IN	0
these	these	DT	0
events	events	NNS	0
in	in	IN	0
the	the	DT	0
two	two	CD	0
treatment	treatment	NN	B-NP
group	group	NN	I-NP
.	.	.	0
hf	hf	NN	B-NP
allhat	allhat	NN	I-NP
criterion	criterion	NN	I-NP
were	were	VBD	0
equivalently	equivalently	VBN	0
met	met	VBN	0
in	in	IN	0
the	the	DT	0
two	two	CD	0
groups	groups	NNS	0
.	.	.	0
While	While	IN	0
the	the	DT	0
sample	sample	NN	0
(	(	-LRB-	0
n	n	CD	0
=	=	SYM	0
50	50	CD	0
)	)	-RRB-	0
of	of	IN	0
hospitalized	hospitalized	NN	0
or	or	CC	0
fatal	fatal	JJ	B-NP
HF	HF	NNP	I-NP
reports	reports	VBZ	0
reviewed	reviewed	VBN	0
by	by	IN	0
the	the	DT	0
allhat	allhat	NN	B-NP
endpoint	endpoint	NN	I-NP
Subcommittee	Subcommittee	NNP	0
was	was	VBD	0
limited	limited	VBN	0
in	in	IN	0
number	number	NN	0
and	and	CC	0
in	in	IN	0
adequacy	adequacy	NN	B-NP
of	of	IN	0
corroborating	corroborating	JJ	0
documentation	documentation	NN	B-NP
,	,	,	0
the	the	DT	0
review	review	NN	0
nonetheless	nonetheless	RB	0
showed	showed	VBD	B-NP
adherence	adherence	VBN	I-NP
to	to	TO	0
study	study	VB	0
criteria	criteria	NNS	0
for	for	IN	0
the	the	DT	0
majority	majority	NN	0
(	(	-LRB-	0
85	85	CD	0
%	%	NN	0
)	)	-RRB-	0
of	of	IN	0
the	the	DT	0
event	event	NN	B-NP
report	report	NN	I-NP
.	.	.	0
The	The	DT	0
sometimes-discrepant	sometimes-discrepant	JJ	B-NP
result	result	NN	I-NP
between	between	IN	0
reviewers	reviewers	JJ	0
pertained	pertained	NN	0
more	more	RBR	0
often	often	RB	0
to	to	TO	0
incomplete	incomplete	JJ	0
data	data	NNS	0
than	than	IN	0
to	to	TO	0
rejection	rejection	NN	0
of	of	IN	0
a	a	DT	0
HF	HF	NNP	B-NP
diagnosis	diagnosis	NN	I-NP
.	.	.	0
Clinical	Clinical	JJ	B-NP
use	use	NN	I-NP
of	of	IN	0
more	more	JJR	0
objective	objective	NN	B-NP
measure	measure	NN	I-NP
,	,	,	0
including	including	VBG	B-NP
noninvasiva	noninvasiva	NN	I-NP
and	and	CC	0
/	/	NNP	0
or	or	CC	0
invasive	invasive	JJ	B-NP
tool	tool	NN	I-NP
for	for	IN	0
the	the	DT	0
measurement	measurement	NN	0
of	of	IN	0
left	left	VBN	0
ventricular	ventricular	JJ	B-NP
function	function	NN	I-NP
,	,	,	0
offers	offers	VBZ	0
a	a	DT	0
means	means	NNS	0
of	of	IN	0
establishing	establishing	VBG	0
and	and	CC	0
quantifying	quantifying	JJ	0
systolic	systolic	JJ	B-NP
failure	failure	NN	I-NP
in	in	IN	0
cases	cases	NNS	0
clinically	clinically	VBP	0
suggestive	suggestive	VBN	0
of	of	IN	0
HF	HF	NNP	B-NP
[	[	-LRB-	0
7	7	CD	0
10	10	CD	0
]	]	-RRB-	0
.	.	.	0
Among	Among	IN	0
the	the	DT	0
ejection	ejection	JJ	B-NP
fraction	fraction	NN	I-NP
reported	reported	VBD	0
in	in	IN	0
the	the	DT	0
allhat	allhat	NN	B-NP
event	event	NN	I-NP
that	that	WDT	0
were	were	VBD	0
reviewed	reviewed	VBN	0
,	,	,	0
the	the	DT	0
majority	majority	NN	0
fell	fell	VBD	0
at	at	IN	0
or	or	CC	0
below	below	IN	0
40	40	CD	0
%	%	NN	0
,	,	,	0
indicating	indicating	VBG	0
some	some	DT	0
degree	degree	NN	0
of	of	IN	0
systolic	systolic	JJ	B-NP
dysfunction	dysfunction	NN	I-NP
.	.	.	0
However	However	RB	0
,	,	,	0
HF	HF	NNP	B-NP
is	is	VBZ	0
a	a	DT	0
clinical	clinical	JJ	B-NP
diagnosis	diagnosis	NN	I-NP
that	that	WDT	0
does	does	VBZ	0
not	not	RB	0
necessarily	necessarily	RB	0
exclude	exclude	VB	0
those	those	DT	0
with	with	IN	0
intact	intact	JJ	0
left	left	JJ	0
ventricular	ventricular	JJ	B-NP
systolic	systolic	JJ	I-NP
function	function	NN	I-NP
[	[	-LRB-	0
11	11	CD	0
]	]	-RRB-	0
.	.	.	0
Hypertension	Hypertension	NNP	0
is	is	VBZ	0
a	a	DT	0
major	major	JJ	0
diastolic	diastolic	JJ	B-NP
hf	hf	NN	I-NP
risk	risk	NN	I-NP
factor	factor	NN	I-NP
;	;	:	0
as	as	IN	0
many	many	JJ	0
as	as	IN	0
25	25	CD	0
%	%	NN	0
of	of	IN	0
asymptomatic	asymptomatic	JJ	B-NP
hypertensive	hypertensive	NN	I-NP
with	with	IN	0
left	left	VBN	0
ventricular	ventricular	JJ	B-NP
hypertrophy	hypertrophy	NN	I-NP
have	have	VBP	0
diastolic	diastolic	JJ	B-NP
dysfunction	dysfunction	NN	I-NP
.	.	.	0
Additionally	Additionally	RB	0
,	,	,	0
90	90	CD	0
%	%	NN	0
of	of	IN	0
patients	patients	NNS	0
with	with	IN	0
coronary	coronary	JJ	B-NP
artery	artery	NN	I-NP
disease	disease	NN	I-NP
may	may	MD	0
have	have	VB	0
some	some	DT	0
degree	degree	NN	0
of	of	IN	0
diastolic	diastolic	JJ	B-NP
dysfunction	dysfunction	NN	I-NP
[	[	-LRB-	0
12	12	CD	0
]	]	-RRB-	0
.	.	.	0
The	The	DT	0
two-fold	two-fold	JJ	B-NP
increased	increased	JJ	0
hf	hf	NN	B-NP
relative	relative	JJ	I-NP
risk	risk	NN	I-NP
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
compared	compared	VBN	0
to	to	TO	0
the	the	DT	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
changed	changed	VBD	0
little	little	RB	0
when	when	WRB	0
confined	confined	VBN	0
to	to	TO	0
hospitalized	hospitalized	VB	0
and	and	CC	0
fatal	fatal	JJ	B-NP
event	event	NN	I-NP
.	.	.	0
Further	Further	RB	0
,	,	,	0
hf	hf	NN	B-NP
patient	patient	JJ	I-NP
in	in	IN	0
both	both	PDT	0
the	the	DT	0
doxazosin	doxazosin	NN	B-NP
and	and	CC	0
chlorthalidone	chlorthalidone	JJ	B-NP
treatment	treatment	NN	I-NP
group	group	NN	I-NP
showed	showed	VBD	0
a	a	DT	0
rather	rather	RB	0
high	high	JJ	0
20	20	CD	0
%	%	NN	0
case-fatality	case-fatality	JJ	B-NP
rate	rate	NN	I-NP
over	over	IN	0
two	two	CD	0
years	years	NNS	0
,	,	,	0
as	as	RB	0
expected	expected	VBN	0
in	in	IN	0
hf	hf	NN	B-NP
patient	patient	JJ	I-NP
[	[	-LRB-	0
11	11	CD	0
13	13	CD	0
14	14	CD	0
]	]	-RRB-	0
,	,	,	0
further	further	RB	0
supporting	supporting	VBG	0
the	the	DT	0
validity	validity	NN	0
of	of	IN	0
the	the	DT	0
diagnoses	diagnoses	NN	0
in	in	IN	0
the	the	DT	0
two	two	CD	0
groups	groups	NNS	0
.	.	.	0
Among	Among	IN	0
participant	participant	NN	B-NP
hospitalized	hospitalized	VBN	0
for	for	IN	0
HF	HF	NNP	B-NP
who	who	WP	0
subsequently	subsequently	RB	0
died	died	VBD	0
,	,	,	0
over	over	IN	0
half	half	NN	0
of	of	IN	0
the	the	DT	0
deaths	deaths	NNS	0
in	in	IN	0
each	each	DT	0
drug	drug	NN	B-NP
group	group	NN	I-NP
were	were	VBD	0
attributed	attributed	VBN	0
to	to	TO	0
cardiovascular	cardiovascular	JJ	B-NP
cause	cause	NN	I-NP
.	.	.	0
treatment	treatment	NN	B-NP
group	group	NN	I-NP
difference	difference	NN	I-NP
in	in	IN	0
mortality	mortality	NN	0
attributed	attributed	VBD	0
to	to	TO	0
HF	HF	NNP	B-NP
may	may	MD	0
take	take	VB	0
time	time	NN	0
to	to	TO	0
be	be	VB	0
recognized	recognized	VBN	0
.	.	.	0
Patients	Patients	NNS	0
with	with	IN	0
HF	HF	NNP	B-NP
are	are	VBP	0
at	at	IN	0
risk	risk	NN	0
for	for	IN	0
other	other	JJ	0
competing	competing	VBG	B-NP
cause	cause	NN	I-NP
of	of	IN	0
death	death	NN	0
.	.	.	0
Accordingly	Accordingly	RB	0
,	,	,	0
it	it	PRP	0
may	may	MD	0
be	be	VB	0
too	too	RB	0
early	early	JJ	0
to	to	TO	0
determine	determine	VB	0
if	if	IN	0
a	a	DT	0
higher	higher	JJR	0
rate	rate	NN	0
of	of	IN	0
HF	HF	NNP	B-NP
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
translates	translates	NN	0
into	into	IN	0
a	a	DT	0
higher	higher	JJR	0
overall	overall	JJ	0
mortality	mortality	NN	B-NP
rate	rate	NN	I-NP
.	.	.	0
A	A	DT	0
20	20	CD	0
%	%	NN	0
2-year	2-year	CD	0
case-fatality	case-fatality	JJ	B-NP
rate	rate	NN	I-NP
with	with	IN	0
a	a	DT	0
4	4	CD	0
%	%	NN	0
difference	difference	NN	0
in	in	IN	0
HF	HF	NNP	B-NP
incidence	incidence	NN	I-NP
rate	rate	NN	I-NP
translates	translates	NN	0
into	into	IN	0
a	a	DT	0
0.8	0.8	CD	0
%	%	NN	0
potential	potential	JJ	B-NP
difference	difference	NN	I-NP
in	in	IN	0
total	total	JJ	B-NP
mortality	mortality	NN	I-NP
without	without	IN	0
any	any	DT	0
competing	competing	JJ	0
causes	causes	NNS	0
of	of	IN	0
death	death	NN	0
.	.	.	0
With	With	IN	0
competing	competing	VBG	B-NP
cause	cause	NN	I-NP
,	,	,	0
the	the	DT	0
difference	difference	NN	0
would	would	MD	0
be	be	VB	0
smaller	smaller	JJR	0
and	and	CC	0
difficult	difficult	JJ	0
to	to	TO	0
detect	detect	VB	0
even	even	RB	0
in	in	IN	0
a	a	DT	0
trial	trial	NN	0
of	of	IN	0
ALLHAT	ALLHAT	NNP	0
's	's	POS	0
size	size	NN	0
.	.	.	0
The	The	DT	0
diagnosis	diagnosis	NN	0
of	of	IN	0
HF	HF	NNP	B-NP
is	is	VBZ	0
generally	generally	RB	0
made	made	VBN	0
on	on	IN	0
the	the	DT	0
basis	basis	NN	0
of	of	IN	0
signs	signs	NNS	0
and	and	CC	0
symptom	symptom	NN	B-NP
that	that	WDT	0
may	may	MD	0
overlap	overlap	VB	0
with	with	IN	0
those	those	DT	0
of	of	IN	0
other	other	JJ	0
cardiovascular	cardiovascular	NN	0
and	and	CC	0
pulmonary	pulmonary	JJ	B-NP
pathology	pathology	NN	I-NP
.	.	.	0
Moreover	Moreover	RB	0
,	,	,	0
the	the	DT	0
clinical	clinical	JJ	B-NP
picture	picture	NN	I-NP
may	may	MD	0
be	be	VB	0
further	further	RB	0
complicated	complicated	VBN	0
for	for	IN	0
patients	patients	NNS	0
taking	taking	VBG	0
doxazosin	doxazosin	NN	B-NP
,	,	,	0
side	side	NN	B-NP
effect	effect	NN	I-NP
of	of	IN	0
which	which	WDT	0
(	(	-LRB-	0
edema	edema	UH	B-NP
,	,	,	0
dyspnea	dyspnea	NN	B-NP
,	,	,	0
and	and	CC	0
tachycardia	tachycardia	CD	B-NP
)	)	-RRB-	0
[	[	-LRB-	0
15	15	CD	0
]	]	-RRB-	0
may	may	MD	0
be	be	VB	0
misinterpreted	misinterpreted	VBN	0
as	as	IN	0
hf	hf	NN	B-NP
manifestation	manifestation	NN	I-NP
.	.	.	0
The	The	DT	0
capture	capture	NN	0
of	of	IN	0
events	events	NNS	0
in	in	IN	0
a	a	DT	0
"large	"large	NNP	0
and	and	CC	0
simple	simple	JJ	0
trial	trial	NN	0
"	"	``	0
such	such	JJ	0
as	as	IN	0
ALLHAT	ALLHAT	NNP	B-NP
has	has	VBZ	0
potential	potential	JJ	B-NP
limitation	limitation	NN	I-NP
.	.	.	0
Built	Built	VBN	0
into	into	IN	0
a	a	DT	0
structure	structure	NN	0
composed	composed	VBN	0
largely	largely	RB	0
of	of	IN	0
community-based	community-based	JJ	0
physicians	physicians	NNS	0
is	is	VBZ	0
the	the	DT	0
assumption	assumption	NN	0
that	that	IN	0
their	their	PRP$	0
clinical	clinical	JJ	B-NP
event	event	NN	I-NP
characterization	characterization	NN	I-NP
reflects	reflects	VBZ	0
medical	medical	JJ	B-NP
community	community	NN	I-NP
diagnostic	diagnostic	JJ	I-NP
standard	standard	JJ	I-NP
,	,	,	0
and	and	CC	0
,	,	,	0
as	as	IN	0
such	such	JJ	0
,	,	,	0
meets	meets	VBZ	0
study	study	NN	B-NP
criterion	criterion	NN	I-NP
.	.	.	0
However	However	RB	0
,	,	,	0
with	with	IN	0
its	its	PRP$	0
large	large	JJ	0
number	number	NN	0
of	of	IN	0
endpoint	endpoint	NN	B-NP
,	,	,	0
resources	resources	NNS	0
available	available	JJ	0
to	to	TO	0
ALLHAT	ALLHAT	NNP	B-NP
precluded	precluded	VBD	0
more	more	JJR	0
than	than	IN	0
modest	modest	JJ	0
confirmatory	confirmatory	JJ	B-NP
event	event	NN	I-NP
documentation	documentation	NN	I-NP
.	.	.	0
Resources	Resources	NNP	0
were	were	VBD	0
allocated	allocated	VBN	0
for	for	IN	0
additional	additional	JJ	0
quality	quality	NN	B-NP
control	control	NN	I-NP
documentation	documentation	NN	I-NP
validation	validation	VBZ	0
only	only	RB	0
for	for	IN	0
a	a	DT	0
sample	sample	NN	0
of	of	IN	0
the	the	DT	0
primary	primary	JJ	B-NP
endpoint	endpoint	NN	I-NP
(	(	-LRB-	0
MIs	MIs	NNP	0
and	and	CC	0
fatal	fatal	JJ	B-NP
CHD	CHD	NNP	I-NP
)	)	-RRB-	0
and	and	CC	0
for	for	IN	0
strokes	strokes	NNS	0
.	.	.	0
While	While	IN	0
all	all	DT	0
reported	reported	JJ	0
events	events	NNS	0
are	are	VBP	0
reviewed	reviewed	VBN	0
at	at	IN	0
the	the	DT	0
CTC	CTC	NNP	B-NP
,	,	,	0
the	the	DT	0
sometimes	sometimes	RB	0
incomplete	incomplete	JJ	0
supporting	supporting	JJ	0
details	details	NNS	0
in	in	IN	0
documentation	documentation	NN	B-NP
may	may	MD	0
not	not	RB	0
allow	allow	VB	0
for	for	IN	0
validation	validation	NN	B-NP
of	of	IN	0
all	all	DT	0
events	events	NNS	0
according	according	VBG	0
to	to	TO	0
allhat	allhat	NN	B-NP
criterion	criterion	NN	I-NP
.	.	.	0
Some	Some	DT	0
discharge	discharge	NN	B-NP
summary	summary	JJ	I-NP
and	and	CC	0
death	death	NN	B-NP
certificate	certificate	NN	I-NP
may	may	MD	0
lack	lack	VB	0
sufficient	sufficient	JJ	0
descriptive	descriptive	JJ	B-NP
information	information	NN	I-NP
needed	needed	VBN	0
to	to	TO	0
confirm	confirm	VB	0
the	the	DT	0
clinical	clinical	JJ	B-NP
diagnosis	diagnosis	NN	I-NP
.	.	.	0
Clinic	Clinic	NNP	0
staff	staff	NN	0
are	are	VBP	0
unable	unable	JJ	0
to	to	TO	0
provide	provide	VB	0
corroborating	corroborating	JJ	0
documentation	documentation	NN	B-NP
for	for	IN	0
2	2	CD	0
%	%	NN	0
of	of	IN	0
allhat	allhat	NN	B-NP
event	event	NN	I-NP
report	report	NN	I-NP
.	.	.	0
Efforts	Efforts	NNS	0
to	to	TO	0
authenticate	authenticate	VB	0
the	the	DT	0
hf	hf	NN	B-NP
event	event	NN	I-NP
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	NN	B-NP
and	and	CC	0
chlorthalidone	chlorthalidone	JJ	B-NP
treatment	treatment	NN	I-NP
group	group	NN	I-NP
represented	represented	VBD	0
a	a	DT	0
desirable	desirable	JJ	0
step	step	NN	0
in	in	IN	0
the	the	DT	0
examination	examination	NN	0
of	of	IN	0
the	the	DT	0
increased	increased	JJ	0
rate	rate	NN	0
of	of	IN	0
HR	HR	NNP	B-NP
in	in	IN	0
the	the	DT	0
doxazosin	doxazosin	JJ	B-NP
group	group	NN	I-NP
.	.	.	0
All	All	DT	0
methods	methods	NNS	0
employed	employed	VBN	0
provided	provided	VBN	0
confirmatory	confirmatory	JJ	B-NP
evidence	evidence	NN	I-NP
that	that	IN	0
both	both	PDT	0
the	the	DT	0
HF	HF	NNP	B-NP
diagnosis	diagnosis	NN	I-NP
and	and	CC	0
the	the	DT	0
difference	difference	NN	0
in	in	IN	0
hf	hf	NN	B-NP
rate	rate	NN	I-NP
noted	noted	VBD	0
between	between	IN	0
the	the	DT	0
doxazosin	doxazosin	NN	B-NP
and	and	CC	0
chlorthalidone	chlorthalidone	JJ	B-NP
group	group	NN	I-NP
were	were	VBD	0
valid	valid	JJ	0
.	.	.	0
Results	Results	NNS	0
of	of	IN	0
this	this	DT	0
exploratory	exploratory	JJ	B-NP
investigation	investigation	NN	I-NP
support	support	NN	I-NP
the	the	DT	0
event	event	NN	B-NP
ascertainment	ascertainment	NN	I-NP
method	method	NN	I-NP
developed	developed	VBN	0
for	for	IN	0
ALLHAT	ALLHAT	NNP	B-NP
,	,	,	0
specifically	specifically	RB	0
for	for	IN	0
hf	hf	NN	B-NP
event	event	NN	I-NP
.	.	.	0
This	This	DT	0
validation	validation	JJ	B-NP
exercise	exercise	NN	I-NP
further	further	RB	0
illustrates	illustrates	VBZ	0
the	the	DT	0
ability	ability	NN	B-NP
of	of	IN	0
large	large	JJ	0
,	,	,	0
simple	simple	JJ	0
trials	trials	NNS	0
to	to	TO	0
answer	answer	VB	0
important	important	JJ	0
public	public	JJ	B-NP
health	health	NN	I-NP
question	question	NN	I-NP
requiring	requiring	VBG	0
large	large	JJ	0
sample	sample	NN	0
sizes	sizes	NNS	0
and	and	CC	0
to	to	TO	0
grapple	grapple	VB	0
with	with	IN	0
unexpected	unexpected	JJ	0
results	results	NNS	0
in	in	IN	0
a	a	DT	0
responsible	responsible	JJ	0
and	and	CC	0
meaningful	meaningful	JJ	0
manner	manner	NN	0
.	.	.	0
competing	competing	VBG	B-NP
interest	interest	NN	I-NP
The	The	DT	0
authors	authors	NNS	0
of	of	IN	0
this	this	DT	0
paper	paper	NN	0
disclose	disclose	VB	0
their	their	PRP$	0
affiliation	affiliation	NN	B-NP
with	with	IN	0
aventi	aventi	NN	B-NP
(	(	-LRB-	0
A	A	NNP	0
)	)	-RRB-	0
,	,	,	0
Abbott	Abbott	NNP	B-NP
(	(	-LRB-	0
abbott	abbott	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
AstraZeneca	AstraZeneca	NNP	B-NP
(	(	-LRB-	0
astrazeneca	astrazeneca	NN	B-NP
)	)	-RRB-	0
,	,	,	0
Bayer	Bayer	NNP	0
(	(	-LRB-	0
B	B	NNP	0
)	)	-RRB-	0
,	,	,	0
Biovail	Biovail	NNP	B-NP
(	(	-LRB-	0
biovail	biovail	NN	B-NP
)	)	-RRB-	0
,	,	,	0
Bristol-Myers	Bristol-Myers	NNP	B-NP
Squibb	Squibb	NNP	I-NP
(	(	-LRB-	0
bristol-myers	bristol-myers	NN	B-NP
squibb	squibb	NNP	I-NP
)	)	-RRB-	0
,	,	,	0
Forest	Forest	NNP	0
(	(	-LRB-	0
F	F	NNP	0
)	)	-RRB-	0
,	,	,	0
Glaxo-SmithKline	Glaxo-SmithKline	NNP	B-NP
/	/	NNP	I-NP
SmithKline	SmithKline	NNP	I-NP
Beecham	Beecham	NNP	I-NP
(	(	-LRB-	0
glaxo-smithkline/smithkline	glaxo-smithkline/smithkline	NN	B-NP
beecham	beecham	NNP	I-NP
)	)	-RRB-	0
,	,	,	0
King	King	NNP	B-NP
Pharmaceuticals	Pharmaceuticals	NNP	I-NP
/	/	NNP	I-NP
Monarch	Monarch	NNP	I-NP
(	(	-LRB-	0
KM	KM	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
Merck	Merck	NNP	0
(	(	-LRB-	0
M	M	NNP	0
)	)	-RRB-	0
,	,	,	0
novarti	novarti	NN	B-NP
(	(	-LRB-	0
N	N	NNP	0
)	)	-RRB-	0
,	,	,	0
Nu-Pharm	Nu-Pharm	NNP	B-NP
(	(	-LRB-	0
NP	NP	NNP	0
)	)	-RRB-	0
,	,	,	0
Pharmacia	Pharmacia	NNP	B-NP
/	/	NNP	I-NP
Upjohn	Upjohn	NNP	I-NP
(	(	-LRB-	0
pharmacia/upjohn	pharmacia/upjohn	NN	B-NP
)	)	-RRB-	0
,	,	,	0
Pfizer	Pfizer	NNP	B-NP
,	,	,	0
Inc.	Inc.	NNP	0
(	(	-LRB-	0
P	P	NN	0
)	)	-RRB-	0
,	,	,	0
Sankyo	Sankyo	NNP	B-NP
(	(	-LRB-	0
sankyo	sankyo	NN	B-NP
)	)	-RRB-	0
,	,	,	0
Searle	Searle	NNP	B-NP
(	(	-LRB-	0
searle	searle	NNP	B-NP
)	)	-RRB-	0
,	,	,	0
Solvay	Solvay	NNP	B-NP
(	(	-LRB-	0
solvay	solvay	NN	B-NP
)	)	-RRB-	0
,	,	,	0
Takeda	Takeda	NNP	0
(	(	-LRB-	0
T	T	NN	0
)	)	-RRB-	0
.	.	.	0
These	These	DT	0
relate	relate	NN	0
to	to	TO	0
personal	personal	JJ	0
or	or	CC	0
institutional-affiliated	institutional-affiliated	JJ	0
receipt	receipt	NN	0
of	of	IN	0
income	income	NN	0
in	in	IN	0
the	the	DT	0
areas	areas	NNS	0
of	of	IN	0
research	research	NN	B-NP
grant	grant	NN	I-NP
,	,	,	0
consultant	consultant	NN	B-NP
fee	fee	NN	I-NP
,	,	,	0
or	or	CC	0
other	other	JJ	0
compensation	compensation	NN	B-NP
:	:	:	0
BRD	BRD	NNP	B-NP
(	(	-LRB-	0
abbott	abbott	NNP	B-NP
,	,	,	0
bristol	bristol	NNP	B-NP
myers	myers	NNP	I-NP
squibb	squibb	NNP	I-NP
,	,	,	0
F	F	NNP	0
,	,	,	0
M	M	NNP	0
,	,	,	0
P	P	NN	0
,	,	,	0
pharmacia/upjohn	pharmacia/upjohn	NN	B-NP
,	,	,	0
glaxo	glaxo	NN	B-NP
smithkline/smithkline	smithkline/smithkline	NN	I-NP
beecham	beecham	NNP	I-NP
)	)	-RRB-	0
,	,	,	0
WCC	WCC	NNP	B-NP
(	(	-LRB-	0
astrazeneca	astrazeneca	NN	B-NP
,	,	,	0
bristol	bristol	NNP	B-NP
myers	myers	NNP	I-NP
squibb	squibb	NNP	I-NP
,	,	,	0
F	F	NNP	0
,	,	,	0
M	M	NNP	0
,	,	,	0
P	P	NN	0
,	,	,	0
pharmacia/upjohn	pharmacia/upjohn	NN	B-NP
,	,	,	0
sankyo	sankyo	NN	B-NP
,	,	,	0
searle	searle	NNP	B-NP
,	,	,	0
solvay	solvay	NN	B-NP
,	,	,	0
T	T	NN	0
)	)	-RRB-	0
,	,	,	0
JTW	JTW	NNP	B-NP
(	(	-LRB-	0
A	A	NNP	0
,	,	,	0
B	B	NNP	0
,	,	,	0
bristol	bristol	NNP	B-NP
myers	myers	NNP	I-NP
squibb	squibb	NNP	I-NP
,	,	,	0
F	F	NNP	0
,	,	,	0
KM	KM	NNP	B-NP
,	,	,	0
M	M	NNP	0
,	,	,	0
N	N	NNP	0
,	,	,	0
P	P	NN	0
)	)	-RRB-	0
,	,	,	0
FHHL	FHHL	NNP	B-NP
(	(	-LRB-	0
astrazeneca	astrazeneca	NN	B-NP
,	,	,	0
B	B	NNP	0
,	,	,	0
bristol	bristol	NNP	B-NP
myers	myers	NNP	I-NP
squibb	squibb	NNP	I-NP
,	,	,	0
M	M	NNP	0
,	,	,	0
NP	NP	NNP	B-NP
,	,	,	0
P	P	NN	0
,	,	,	0
pharmacia/upjohn	pharmacia/upjohn	NN	B-NP
)	)	-RRB-	0
,	,	,	0
LJH	LJH	NNP	B-NP
(	(	-LRB-	0
pharmacia/upjohn	pharmacia/upjohn	NN	B-NP
)	)	-RRB-	0
;	;	:	0
the	the	DT	0
other	other	JJ	0
authors	authors	NNS	0
report	report	VBP	0
no	no	RB	0
competing	competing	VBG	B-NP
interest	interest	NN	I-NP
.	.	.	0
Additional	Additional	JJ	B-NP
Information	Information	NNP	I-NP
1	1	CD	0
)	)	-RRB-	0
functional	functional	JJ	B-NP
class	class	NN	I-NP
iii	iii	NN	I-NP
new	new	JJ	I-NP
york	york	NNP	I-NP
heart	heart	NN	I-NP
classification	classification	NN	I-NP
:	:	:	0
"Patients	"Patients	CD	0
with	with	IN	0
cardiac	cardiac	JJ	B-NP
disease	disease	NN	I-NP
resulting	resulting	VBG	0
in	in	IN	0
marked	marked	JJ	0
limitation	limitation	NN	0
of	of	IN	0
physical	physical	JJ	B-NP
activity	activity	NN	I-NP
.	.	.	0
They	They	PRP	0
are	are	VBP	0
comfortable	comfortable	JJ	0
at	at	IN	0
rest	rest	NN	0
.	.	.	0
Less	Less	RBR	0
than	than	IN	0
ordinary	ordinary	JJ	B-NP
physical	physical	JJ	I-NP
activity	activity	NN	I-NP
causes	causes	VBZ	0
fatigue	fatigue	VBN	0
,	,	,	0
palpitation	palpitation	NN	0
,	,	,	0
dyspnea	dyspnea	NN	B-NP
,	,	,	0
or	or	CC	0
anginal	anginal	JJ	B-NP
pain.	pain.	NN	I-NP
"	"	''	0
1994	1994	CD	0
Revisions	Revisions	NNS	0
to	to	TO	0
functional	functional	JJ	B-NP
capacity	capacity	NN	I-NP
classification	classification	NN	I-NP
and	and	CC	0
Objective	Objective	NNP	B-NP
Assessment	Assessment	NNP	I-NP
of	of	IN	0
Patients	Patients	NNS	0
with	with	IN	0
Diseases	Diseases	NNP	0
of	of	IN	0
the	the	DT	0
Heart	Heart	NNP	0
:	:	:	0
AHA	AHA	NNP	B-NP
Medical	Medical	NNP	I-NP
/	/	NNP	I-NP
Scientific	Scientific	NNP	I-NP
Statement.	Statement.	CD	I-NP
2	2	CD	0
)	)	-RRB-	0
The	The	DT	0
ALLHAT	ALLHAT	NNP	B-NP
Manual	Manual	NNP	I-NP
of	of	IN	0
Operations	Operations	NNP	0
provides	provides	VBZ	0
for	for	IN	0
open-label	open-label	JJ	B-NP
medicine	medicine	NN	I-NP
prescription	prescription	NN	I-NP
of	of	IN	0
the	the	DT	0
same	same	JJ	0
class	class	NN	0
as	as	IN	0
the	the	DT	0
blinded	blinded	JJ	0
medications	medications	NN	0
,	,	,	0
when	when	WRB	0
a	a	DT	0
compelling	compelling	JJ	0
indication	indication	NN	0
exists	exists	VBZ	0
,	,	,	0
such	such	JJ	0
that	that	IN	0
the	the	DT	0
total	total	JJ	B-NP
dose	dose	NN	I-NP
of	of	IN	0
the	the	DT	0
added	added	JJ	0
open-label	open-label	JJ	B-NP
drug	drug	NN	I-NP
should	should	MD	0
not	not	RB	0
exceed	exceed	VB	0
1	1	CD	0
/	/	CD	0
2	2	CD	0
of	of	IN	0
the	the	DT	0
maximum	maximum	JJ	0
dose	dose	NN	0
as	as	IN	0
recommended	recommended	VBN	0
in	in	IN	0
the	the	DT	0
Sixth	Sixth	NNP	B-NP
Report	Report	NNP	I-NP
of	of	IN	0
the	the	DT	0
Joint	Joint	NNP	0
National	National	NNP	B-NP
Committee	Committee	NNP	I-NP
on	on	IN	0
Detection	Detection	NNP	0
,	,	,	0
Evaluation	Evaluation	NNP	0
and	and	CC	0
Treatment	Treatment	NNP	0
of	of	IN	0
High	High	NNP	0
Blood	Blood	NNP	0
Pressure	Pressure	NNP	0
(	(	-LRB-	0
JNC	JNC	NNP	B-NP
VI	VI	NNP	I-NP
)	)	-RRB-	0
.	.	.	0
If	If	IN	0
a	a	DT	0
compelling	compelling	JJ	0
reason	reason	NN	0
requires	requires	VBZ	0
a	a	DT	0
higher	higher	JJR	0
dose	dose	NN	0
,	,	,	0
it	it	PRP	0
is	is	VBZ	0
permitted.	permitted.	CD	0
3	3	CD	0
)	)	-RRB-	0
The	The	DT	0
ALLHAT	ALLHAT	NNP	B-NP
follow-up	follow-up	JJ	I-NP
form	form	NN	I-NP
allows	allows	VBZ	0
for	for	IN	0
reporting	reporting	VBG	0
of	of	IN	0
open-label	open-label	JJ	B-NP
ace-inhibitor	ace-inhibitor	NN	I-NP
and	and	CC	0
diuretic	diuretic	NN	B-NP
;	;	:	0
among	among	IN	0
beta-blocker	beta-blocker	NN	B-NP
,	,	,	0
only	only	JJ	0
atenolol	atenolol	NN	B-NP
is	is	VBZ	0
reported	reported	VBN	0
.	.	.	0
The	The	DT	0
use	use	NN	0
of	of	IN	0
other	other	JJ	0
beta-blocker	beta-blocker	NN	B-NP
cannot	cannot	NNS	0
be	be	VB	0
ascertained	ascertained	VBN	0
from	from	IN	0
the	the	DT	0
data	data	NNS	0
.	.	.	0
